The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (4th Edition) by Scale of Operation (Lab, Clinical and Commercial), Type of Vector (AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA and Others), Application Area (Gene Therapy, Cell Therapy and Vaccine), Therapeutic Area, and Geographical Regions (North America, Europe, Asia Pacific, MENA, Latin America and Rest of the World): Industry Trends and Global Forecasts, 2021-2030

  • Lowest Price Guaranteed From USD 5,899

  • Published
    January 2021

  • Pages
    689

  • View Count
    22571

Example Insights

Viral-Vectors-Non-Viral-Vectors-and-Gene-Therapy-Manufacturing-Market-Context Viral-Vectors-Non-Viral-Vectors-and-Gene-Therapy-Manufacturing-Market-Example-highlights Viral-Vectors-Non-Viral-Vectors-and-Gene-Therapy-Manufacturing-Market-Industry-Players Viral-Vectors-Non-Viral-Vectors-and-Gene-Therapy-Manufacturing-Market-Different-scales
Viral-Vectors-Non-Viral-Vectors-and-Gene-Therapy-Manufacturing-Market-Geographical-Distribution Viral-Vectors-Non-Viral-Vectors-and-Gene-Therapy-Manufacturing-Market-Company-Competitiveness-Analysis Viral-Vectors-Non-Viral-Vectors-and-Gene-Therapy-Manufacturing-Market-Recent-Expansions Viral-Vectors-Non-Viral-Vectors-and-Gene-Therapy-Manufacturing-Market-Distribution-by-Type-of-Technology
Viral-Vectors-Non-Viral-Vectors-and-Gene-Therapy-Manufacturing-Market-AAV-Manufacturing Viral-Vectors-Non-Viral-Vectors-and-Gene-Therapy-Manufacturing-Market-Emerging-Vectors Viral-Vectors-Non-Viral-Vectors-and-Gene-Therapy-Manufacturing-Market-Capacity-Analysis Viral-Vectors-Non-Viral-Vectors-and-Gene-Therapy-Manufacturing-Market-Current-demand
Viral-Vectors-Non-Viral-Vectors-and-Gene-Therapy-Manufacturing-Market-Analysis-of-Demand-and-Supply-Dynamics Viral-Vectors-Non-Viral-Vectors-and-Gene-Therapy-Manufacturing-Market-Opportunity Viral-Vectors-Non-Viral-Vectors-and-Gene-Therapy-Manufacturing-Market-Future-Forecast

 

Overview

Over the past few years, a number of advanced therapy medicinal products, including cell and gene therapies, have been developed and approved for the treatment of a variety of disease indications. In fact, as of 2020, close to 15 such therapeutics have received marketing approval across different regions worldwide. Further, over 1,000 clinical trials focused on the evaluation of cell and gene therapies have been registered globally. It is worth noting that the clinical success of these therapies heavily relies on the design and type of gene delivery vector used (in therapy development and / or administration). At present, several innovator companies are actively engaged in developing / producing viral and / or non-viral vectors for gene therapies. In this context, it is worth mentioning that multiple viral and non-viral vector based vaccine candidates are being developed against the novel coronavirus (SARS-CoV-2). As of January 2021, the WHO revealed that more than 55 such vaccines are under evaluation, while two viral vector based vaccines (AZD1222 and Sputnik V), being developed by AstraZeneca / Oxford University and Gamaleya Research Institute / Acellena Contract Drug Research and Development, have been approved. This is indicative of the lucrative opportunities for companies that have the required capabilities to manufacture vectors and gene therapies.

Vaccine production is a challenging process and dealing with vectors (viral and non-viral) further adds to the complexity. Therefore, outsourcing is a common practice among biopharmaceutical companies when it comes to vector development and / or manufacturing. Several players have developed / are developing versatile technology platforms for designing and manufacturing different types of gene delivery vehicles. Innovation in this segment of the pharmaceutical industry is presently focused on the enhancement of transduction efficiency and improving gene delivery efficiencies. In fact, some vector-related technology providers claim that their proprietary solutions have the ability to enable further improvements in existing genetically modified therapeutic products, and / or optimize affiliated manufacturing processes. The viral / non-viral vectors and gene therapy manufacturing market has also witnessed significant partnership activity in the recent past, especially now that COVID-19 vaccine developers are actively approaching such companies for their services. Given the growing demand for interventions that require genetic modification, the vector and gene therapy manufacturing market is poised to witness substantial growth in the foreseen future.

Scope of the Rpeort

The “Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (4th Edition) by Scale of Operation (Preclinical, Clinical and Commercial), Type of Vector (AAV Vector, Adenoviral Vector, Lentiviral Vector, Retroviral Vector, Plasmid DNA and Others), Application Area (Gene Therapy, Cell Therapy and Vaccine), Therapeutic Area (Oncological Disorders, Inflammation & Immunological Diseases, Neurological Disorders, Ophthalmic Disorders, Muscle Disorders, Metabolic Disorders, Cardiovascular Disorders and Others), and Geographical Regions (North America, Europe, Asia Pacific, MENA, Latin America and Rest of the World): Industry Trends and Global Forecasts, 2021-2030” report features an extensive study of the rapidly growing market of vector and gene therapy manufacturing, focusing on contract manufacturers, as well as companies having in-house manufacturing facilities. The study presents an in-depth analysis of the various firms / organizations that are engaged in this domain, across different regions of the globe. Amongst other elements, the report includes:

  • An overview of the current status of the market with respect to the players engaged (both industry and non-indutry) in the manufacturing of viral, non-viral and other novel types of vectors, and gene therapies. It features information on the year of establishment, company size, location of headquarters, type of product manufactured (vector and gene therapy / cell therapy / vaccine), location of manufacturing facilities, purpose of production (in-house and contract services), scale of production (preclinical, clinical and commercial), type of vector manufactured (AAV, adenoviral, lentiviral, retroviral, plasmid DNA and others) and application area (gene therapy, cell therapy, vaccine and others).
  • An analysis of the technologies offered / developed by the companies enagaged in this domain, based on the type of technology (viral vector and non-viral vector related platform), purpose of technology (vector manufacturing, gene delivery, product manufacturing, transduction / transfection, vector packaging and other), scale of production (preclinical, clinical and clinical), type of vector (AAV, adenoviral, lentiviral, retroviral, non-viral and other viral vectors), application area (gene therapy, cell therapy, vcaccine and others). It also highlights the most prominent players within this domain, in terms of number of technologies.
  • A region-wise, company competitiveness analysis, highlighting key players engaged in the manufacturing of vectors and gene therapies, across key geographical areas, featuring a four-dimensional bubble representation, taking into consideration supplier strength (based on experience in this field), manufacturing strength (type of product manufactured, number of manufacturing facilites and number of application areas), service strength (scale of operation, number of vectors manufactured and geographical reach) and company size (small-sized, mid-sized and large).
  • Elaborate profiles of key players based in North America, Europe and Asia-Pacific (shortlisted based on proprietary criterion). Each profile features an overview of the company / organization, its financial performance (if available), information related to its manufacturing facilities, vector manufacturing technology and an informed future outlook.
  • An analysis of recent collaborations  and partnership agreements inked in this domain since 2015; it includes details of deals that were / are focused on the manufacturing of vectors, which were analyzed on the basis of year of partnership, type of partnership (manufacturing agreement, product / technology licensing, product development, merger / acqusition, research and development agreement, process development  / optimization, service alliance, production asset / facility acquisition, supply agreement and others), scale of production (laboratory, clinical and commercial), type of vector (AAV, adenoviral, lentiviral, retroviral, plasmid and others), region and most active players (in terms of number of partnerships). 
  • An analysis of the expansions related to viral vector and non-viral vector manufacturing, which have been undertaken since 2015, based on several parameters, such as year of expansion, type of expansion (new facility / plant establishment, facility expansion, technology installation / expansion, capacity expansion and others), type of vector (AAV, adenoviral, lentiviral, retroviral, plasmid and others), application area (gene therapy, cell therapy, vaccine and others) and geographical location of the expansion project.
  • An analysis evaluating the potential strategic partners (comparing vector based therapy developers and vector purification product developers) for vector and gene therapy product manufacturers, based on several parameters, such as developer strength, product strength, type of vector, therapeutic area, pipeline strength (clinical and preclinical).
  • An overview of other viral / non-viral gene delivery approaches that are currently being researched for the development of therapies involving genetic modification.
  • An in-depth analysis of viral vector and plasmid DNA manufacturers, featuring three schematic representations, namely [A] a three dimensional grid analysis, representing the distribution of vector manufacturers (on the basis of type of vector) across various scales of operation and purpose of production (in-house operations and contract manufacturing services), [B] a logo landscape of viral vector and plasmid DNA manufacturers based on the type of organization (industry and non-industry) and comapny size (small-sized, mid-sized and large), and [C] a schematic world map representation, highlighting the geographical location of key vector manufacturing hubs.
  • An analysis of the various factors that are likely to influence the pricing of vectors, featuring different models / approaches that may be adopted by product developers / manufacturers in order to decide the prices of proprietary vectors.
  • An estimate of the overall, installed vector manufacturing capacity of industry players based on the information available in the public domain, and insights generated via both secondary and primary research. The analysis also highlights the distribution of the global capacity by company size (small-sized, mid-sized and large), scale of operation (clinical and commercial), type of vector (viral vector and plasmid DNA) and region (North America, Europe, Asia Pacific and the rest of the world).
  • An informed estimate of the annual demand for viral and non-viral vectors, taking into account the marketed gene-based therapies and clinical studies evaluating vector-based therapies; the analysis also takes into consideration various relevant parameters, such as target patient population, dosing frequency and dose strength.
  • A discussion on the factors driving the market and various challenges associated with the vector production process.
  • An insightful discussion on the impact that the recent COVID-19 pandemic is likely to have on the vector and gene therapy manufacturing market. In addition, it features various strategies that different companies have adopted / may adopt in order to mitigate the challenges affiliated to the current global crisis.

One of the key objectives of this report was to evaluate the current market size and the future opportunity associated with the vector and gene therapy manufacturing market, over the coming decade. Based on various parameters, such as the likely increase in number of clinical studies, anticipated growth in target patient population, existing price variations across different types of vectors, and the anticipated success of gene therapy products (considering both approved and late-stage clinical candidates), we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2021-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of  [A] scale of operation (preclinical, clinical and commercial), [B] type of vector (AAV vector, adenoviral vector, lentiviral vector, retroviral vector, plasmid DNA and others), [C] application area (gene therapy, cell therapy and vaccine), [D] therapeutic area (oncological disorders, inflammation & immunological diseases, neurological disorders, ophthalmic disorders, muscle disorders, metabolic disorders, cardiovascular disorders and others) and [E] geographical region (North America, Europe, Asia Pacific, MENA, Latin America and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
    
The research, analysis and insights presented in this report are backed by a deep understanding of key insights generated from both secondary and primary research. For the purpose of the study, we invited over 180 stakeholders to participate in a survey to solicit their opinions on upcoming opportunities and challenges that must be considered for a more inclusive growth. The opinions and insights presented in this study were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry and non-industry players:

  • Menzo Havenga (Chief Executive Officer and President, Batavia Biosciences)
  • Nicole Faust (Chief Executive Officer & Chief Scientific Officer, CEVEC Pharmaceuticals)
  • Jeffrey Hung (Chief Commercial Officer, Vigene Biosciences)
  • Cedric Szpirer (Founder, Executive & Scientific Director, Delphi Genetics)
  • Olivier Boisteau, (Co-Founder / President, Clean Cells), Laurent Ciavatti (Ex-Business Development Manager, Clean Cells) and Xavier Leclerc (Head of Gene Therapy, Clean Cells)
  • Alain Lamproye (Ex-President of Biopharma Business Unit, Novasep)
  • Joost van den Berg (Ex-Director, Amsterdam BioTherapeutics Unit)
  • Bakhos A Tannous (Director, MGH Viral Vector Development Facility, Massachusetts General Hospital)
  • Eduard Ayuso, DVM, PhD (Scientific Director, Translational Vector Core, University of Nantes)
  • Colin Lee Novick (Managing Director, CJ Partners)
  • Semyon Rubinchik (Scientific Director, ACGT)
  • Astrid Brammer (Senior Manager Business Development, Richter-Helm)
  • Marco Schmeer (Project Manager, Plasmid Factory) and Tatjana Buchholz (Ex-Marketing Manager, Plasmid Factory)
  • Brain M Dattilo (Business Development Manager, Waisman Biomanufacturing)
  • Beatrice Araud (ATMP Key Account Manager, EFS-West Biotherapy)
  • Nicolas Grandchamp (R&D Leader, GEG Tech)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading players (contract service providers and in-house manufacturers) engaged in the development of vectors and gene therapies?
  • Which region are the current manufacturing hubs for vectors and gene therapies?
  • Which type of technologies are presently offered / being developed by the stakeholders engaged in this domain?
  • Which companies are likely to partner with viral and non-viral vector contract manufacturing service providers?
  • Which partnership models are commonly adopted by stakeholders engaged in this industry?
  • What type of expansion initiatives are being undertaken by players in this domain?
  • Which are the emerging viral and non-viral vectors used by players for the manufacturing of genetically modified therapies?
  • How is the recent COVID-19 pandemic likely to impact the viral and non-viral vector, and gene therapy manufacturing market?
  • What is the current, global demand for viral and non-viral vector, and gene therapies?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the vector and gene therapy manufacturing market in the short to mid-term, and long term.

Chapter 3 is a general introduction to the various types of viral and non-viral vectors. It includes a detailed discussion on the design, manufacturing requirements, advantages, limitations and applications of the currently available gene delivery vehicles. The chapter also features the clinical and approved pipeline of genetically modified therapies. Further, it includes a review of the latest trends and innovations in the contemporary vector manufacturing market. 

Chapter 4 provides a detailed overview of more than 115 companies, featuring both contract service providers and in-house manufacturers that are actively involved in the production of viral vectors and / or gene therapies utilizing viral vectors. The chapter provides details on the year of establishment, company size, location of headquarters, type of product manufactured (vector and gene therapy / cell therapy / vaccine), location of manufacturing facilities, purpose of production (in-house and contract services), scale of production (preclinical, clinical and commercial), type of vector manufactured (AAV, adenoviral, lentiviral, retroviral, plasmid DNA and others) and application area (gene therapy, cell therapy, vaccine and others). 

Chapter 5 provides an overview of around 65 industry players that are actively involved in the production of plasmid DNA and other non-viral vectors and / or gene therapies utilizing non-viral vectors. The chapter provides details on the the year of establishment, company size, location of headquarters, type of product manufactured (vector and gene therapy / cell therapy vaccine), location of plasmid DNA manufacturing facilities, purpose of production (in-house and contract services), scale of production (preclinical, clinical and commercial) and application area (gene therapy, cell therapy, vaccine and others).

Chapter 6 provides an overview of close to 90 non-industry players (academia and research institutes) that are actively involved in the production of vectors (both viral and non-viral) and / or gene therapies. The chapter provides details on the year of establishment, purpose of production (in-house and contract services), scale of production (preclinical, clinical and commercial), location of headquarters, type of vector manufactured (AAV, adenoviral, lentiviral, retroviral, plasmid DNA and others) and application area (gene therapy, cell therapy, vaccine and others).

Chapter 7 features an in-depth analysis of the technologies offered / developed by the companies engaged in this domain, based on the type of technology (viral vector and non-viral vector related platform), purpose of technology (vector manufacturing, gene delivery, product manufacturing, transduction / transfection, vector packaging and other), scale of production (preclinical, clinical and clinical), type of vector (AAV, adenoviral, lentiviral, retroviral, non-viral and other viral vectors), application area (gene therapy, cell therapy, vaccine and others) and leading technology providers.

Chapter 8 presents a detailed competitiveness analysis of vector manufacturers across key geographical areas, featuring a four-dimensional bubble representation, taking into consideration supplier strength (based on its experience in this field), manufacturing strength (type of product manufactured, number of manufacturing facilities and number of application area), service strength (scale of production, number of vectors manufactured and geographical reach) and company size (small-sized, mid-sized and large).

Chapter 9 features detailed profiles of some of the key players that have the capability to manufacture viral vectors / plasmid DNA in North America. Each profile presents a brief overview of the company, its financial information (if available), details on vector manufacturing facilities, manufacturing experience and an informed future outlook.

Chapter 10 features detailed profiles of some of the key players that have the capability to manufacture viral vectors / plasmid DNA in Europe. Each profile presents a brief overview of the company, its financial information (if available), details on vector manufacturing facilities, manufacturing experience and an informed future outlook.

Chapter 11 features detailed profiles of some of the key players that have the capability to manufacture viral vectors / plasmid DNA in Asia-Pacific. Each profile presents a brief overview of the company, its financial information (if available), details on vector manufacturing facilities, manufacturing experience and an informed future outlook.

Chapter 12 features in-depth analysis and discussion of the various partnerships inked between the players in this market, during the period, 2015-2020, covering analysis based on parameters such as year of partnership, type of partnership(manufacturing agreement, product / technology licensing, product development, merger / acquisition, research and development agreement, process development  / optimization, service alliance, production asset / facility acquisition, supply agreement and others), scale of production (laboratory, clinical and commercial) and type of vector (AAV, adenoviral, lentiviral, retroviral, plasmid and others) most active players (in terms of number of partnerships).

Chapter 13 features an elaborate discussion and analysis of the various expansions that have been undertaken, since 2015. Further, the expansion activities in this domain have been analyzed on the basis of year of expansion, type of expansion (new facility / plant establishment, facility expansion, technology installation / expansion, capacity expansion and others), geographical location of the facility, type of vector (AAV, adenoviral, lentiviral, retroviral, plasmid and others) and application area (gene therapy, cell therapy, vaccine and others).

Chapter 14 highlights potential strategic partners (vector based therapy developers and vector purification product developers) for vector and gene therapy product manufacturers, based on several parameters, such as developer strength, product strength, type of vector, therapeutic area, pipeline strength (clinical and preclinical). The analysis aims to provide the necessary inputs to the product developers, enabling them to make the right decisions to collaborate with industry stakeholders with relatively more initiatives in the domain.

Chapter 15 provides detailed information on other viral / non-viral vectors (including alphavirus vectors, Bifidobacterium longum vectors, Listeria monocytogenes vectors, myxoma virus based vectors, Sendai virus based vectors, self-complementary vectors (improved versions of AAV), and minicircle DNA and Sleeping Beauty transposon vectors (non-viral gene delivery approach)) that are currently being utilized by pharmaceutical players to develop gene therapies, T-cell therapies and certain vaccines, as well. This chapter presents overview on all the aforementioned types of vectors, along with examples of companies that use them in their proprietary products. It also includes examples of companies that are utilizing specific technology platforms for the development / manufacturing of some of these novel vectors. 

Chapter 16 presents a collection of key insights derived from the study. It includes a grid analysis, highlighting the distribution of viral vectors and plasmid DNA manufacturers on the basis of their scale of production and purpose of manufacturing (fulfilling in-house requirement / contract service provider). In addition, it consists of a logo landscape, representing the distribution of viral vector and plasmid DNA manufacturers based on the type of organization (industry / non-industry) and company size. The chapter also consists of six world map representations of manufacturers of viral / non-viral vectors (lentiviral, adenoviral, AAV and retroviral vectors, and plasmid DNA), depicting the most active geographies in terms of the presence of the organizations. Furthermore, we have provided a schematic world map representation to highlight the geographical locations of key vector manufacturing hubs across different continents. 

Chapter 17 highlights our views on the various factors that may be taken into consideration while pricing viral vectors / plasmid DNA. It features discussions on different pricing models / approaches that manufacturers may choose to adopt to decide the prices of their proprietary products.

Chapter 18 features an informed analysis of the overall installed capacity of the vectors and gene therapy manufacturers. The analysis is based on meticulously collected data (via both secondary and primary research) on reported capacities of various small-sized, mid-sized and large companies, distributed across their respective facilities. The results of this analysis were used to establish an informed opinion on the vector production capabilities of the organizations by company size (small-sized, mid-sized and large), scale of operation (clinical and commercial), type of vector (viral vector and plasmid DNA) and region (North America, Europe, Asia Pacific and the rest of the world).

Chapter 19 features an informed estimate of the annual demand for viral and non-viral vectors, taking into account the marketed gene-based therapies and clinical studies evaluating vector-based therapies. This section offers an opinion on the required scale of supply (in terms of vector manufacturing services) in this market. For the purpose of estimating the current clinical demand, we considered the active clinical studies of different types of vector-based therapies that have been registered till date. The data was analyzed on the basis of various parameters, such as number of annual clinical doses, trial location, and the enrolled patient population across different geographies. Further, in order to estimate the commercial demand, we considered the marketed vector-based therapies, based on various parameters, such as target patient population, dosing frequency and dose strength.

Chapter 20 presents a comprehensive market forecast analysis, highlighting the likely growth of vector and gene therapy manufacturing market till the year 2030. We have segmented the financial opportunity on the basis of [A] type of vectors (AAV vector, adenoviral vector, lentiviral vector, retroviral vector, plasmid DNA and others), [B] applications (gene therapy, cell therapy and vaccine), [C] therapeutic area (oncological disorders, inflammation & immunological diseases, neurological disorders, ophthalmic disorders, muscle disorders, metabolic disorders, cardiovascular disorders and others), [D] scale of operation (preclinical, clinical and commercial) and [E] geography (North America, Europe, Asia Pacific, MENA, Latin America and rest of the world). Due to the uncertain nature of the market, we have presented three different growth tracks outlined as the conservative, base and optimistic scenarios.

Chapter 21 highlights the effect of recent coronavirus outbreak on the vector and gene therapy manufacturing market. It includes a brief discussion on the short-term and long-term impact of COVID-19 on the supply chain and market opportunity for vector and gene therapy manufacturers. In addition, it includes a brief section on strategies and action plans that pharmaceutical and biopharmaceutical companies are likely to adopt in order to prepare for supply chain disruptions in future.

Chapter 22 provides details on the various factors associated with popular viral vectors and plasmid DNA that act as market drivers and the various challenges associated with the production process. This information has been validated by soliciting the opinions of several industry stakeholders active in this domain.

Chapter 23 presents insights from the survey conducted on over 180 stakeholders involved in the development of different types of gene therapy vectors. The participants, who were primarily Director / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 24 summarizes the overall report. The chapter presents a list of key takeaways and offers our independent opinion on the current market scenario and evolutionary trends that are likely to determine the future of this segment of the industry.

Chapter 25 is a collection of transcripts of the interviews conducted with representatives from renowned organizations that are engaged in the vector and gene therapy manufacturing domain. In this study, we spoke to Menzo Havenga (Chief Executive Officer and President, Batavia Biosciences), Nicole Faust (Chief Executive Officer & Chief Scientific Officer, CEVEC Pharmaceuticals), Jeffrey Hung (Chief Commercial Officer, Vigene Biosciences), Cedric Szpirer (Founder, Executive & Scientific Director, Delphi Genetics), Olivier Boisteau, (Co-Founder / President, Clean Cells), Laurent Ciavatti (Ex-Business Development Manager, Clean Cells) and Xavier Leclerc (Head of Gene Therapy, Clean Cells), Alain Lamproye (Ex-President of Biopharma Business Unit, Novasep), Joost van den Berg (Ex-Director, Amsterdam BioTherapeutics Unit), Bakhos A Tannous (Director, MGH Viral Vector Development Facility, Massachusetts General Hospital), Eduard Ayuso, DVM, PhD (Scientific Director, Translational Vector Core, University of Nantes), Colin Lee Novick (Managing Director, CJ Partners), Semyon Rubinchik (Scientific Director, ACGT), Astrid Brammer (Senior Manager Business Development, Richter-Helm), Marco Schmeer (Project Manager, Plasmid Factory) and Tatjana Buchholz (Ex-Marketing Manager, Plasmid Factory), Brain M Dattilo (Business Development Manager, Waisman Biomanufacturing), Beatrice Araud (ATMP Key Account Manager, EFS-West Biotherapy) and Nicolas Grandchamp (R&D Leader, GEG Tech)

Chapter 26 is an appendix, which provides tabulated data and numbers for all the figures in the report.

Chapter 27 is an appendix that provides the list of companies and organizations that have been mentioned in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Viral and Non-Viral Gene Transfer Techniques 
3.3. Viral Vectors Used in Genetically Modified Therapies

3.4. Types of Viral Vectors
3.4.1. Adeno-associated Viral Vectors
3.4.2. Adenoviral Vectors
3.4.3. Lentiviral Vectors
3.4.4. Retroviral Vectors
3.4.5. Other Viral Vectors
3.4.5.1. Alphavirus
3.4.5.2. Foamy Virus
3.4.5.3. Herpes Simplex Virus
3.4.5.4. Sendai Virus
3.4.5.5. Simian Virus
3.4.5.6. Vaccinia Virus

3.5. Types of Non-Viral Vectors
3.5.1. Plasmid DNA
3.5.2. Liposomes, Lipoplexes and Polyplexes
3.5.3. Oligonucleotides
3.5.4. Other Non-Viral Vectors

3.6. Gene Delivery using Non-Viral Vectors
3.6.1. Biolistic Methods
3.6.2. Electroporation
3.6.3. Receptor Mediated Gene Delivery
3.6.4. Gene Activated Matrix (GAM)

3.7. Applications of Viral and Non-Viral Vectors
3.7.1. Type of Therapy
3.7.1.1. Cell and Gene Therapy
3.7.1.2. Vaccinology

3.8. Current / Ongoing Trends in Vector Development / Manufacturing
3.8.1. Vector Engineering
3.8.2. Cargo Engineering

3.9. Vector Manufacturing
3.9.1. Types of Vector Manufacturers
3.9.2. Viral Vector Manufacturing Processes
3.9.2.1 Vector Production
3.9.2.2. Adherent and Suspension Cultures
3.9.2.3. Unit Process Versus Multiple Parallel Processes
3.9.2.4. Cell Culture Systems for Production of Viral Vectors
3.9.2.5. Serum-Containing versus Serum-Free Media

3.9.3. Bioprocessing of Viral Vectors
3.9.3.1. AAV Vector Production
3.9.3.2. Adenoviral Vector Production
3.9.3.3. Lentiviral Vector Production
3.9.3.4. γ -Retroviral Vector Production
3.9.4. Key Challenges Associated with Vector Manufacturing

3.10. Future Perspectives

4. VIRAL VECTOR AND GENE THERAPY MANUFACTURERS (INDUSTRY PLAYERS): MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Viral Vector and Gene Therapy Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Type of Product Manufactured

4.2.5. Analysis by Location of Vector Manufacturing Facilities
4.2.6. Analysis by Purpose of Production
4.2.7. Analysis by Scale of Production
4.2.8. Analysis by Location of Headquarters and Scale of Production
4.2.9. Analysis by Type of Vector Manufactured
4.2.10. Analysis by Scale of Production and Type of Vector Manufactured
4.2.11. Analysis by Application Area
4.2.12. Information on Production Capacity

5. PLASMID DNA AND GENE THERAPY MANUFACTURERS (INDUSTRY PLAYERS): MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Plasmid DNA and Gene Therapy Manufacturers: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Heat Map: Analysis by Company Size and Location of Headquarters

5.2.5. Analysis by Type of Product Manufactured
5.2.6. Analysis by Location of Plasmid DNA Manufacturing Facilities
5.2.7. Analysis by Purpose of Production
5.2.8. Analysis by Scale of Production
5.2.9. Analysis by Application Area
5.2.10. Information on Production Capacity

6. VECTOR AND GENE THERAPY MANUFACTURERS (NON-INDUSTRY PLAYERS): MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Vector and Gene Therapy Manufacturers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Location of Vector Manufacturing Facilities
6.2.3. Analysis by Purpose of Production
6.2.4. Analysis by Scale of Production
6.2.5. Analysis by Type of Vector Manufactured
6.2.6. Analysis by Scale of Production and Type of Vector Manufactured
6.2.7. Analysis by Application Area

7. VECTOR AND GENE THERAPY MANUFACTURING TECHNOLOGIES: MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Vector and Gene Therapy Manufacturing Technologies
7.2.1. Analysis by Type of Technology
7.2.2. Analysis by Purpose of Technology
7.2.3. Analysis by Scale of Production
7.2.4. Analysis by Type of Vector
7.2.5. Analysis by Application Area
7.2.6. Most Active Players: Analysis by Type of Technology
7.3. Concluding Remarks

8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Methodology and Key Parameters
8.3. Vector and Gene Therapy: In-House Manufacturers
8.3.1. Players based in North America
8.3.2. Players based in Europe
8.3.3. Players based in Asia-Pacific and Rest of the World

8.4. Vector and Gene Therapy: Contract Manufacturing Organizations
8.4.1. Players based in North America
8.4.2. Players based in Europe
8.4.3. Players based in Asia-Pacific and Rest of the World

8.5.. Vector and Gene Therapy: Players Engaged in In-house and Contract Manufacturing
8.5.1. Players based in North America
8.5.2. Players based in Europe
8.5.3. Players based in Asia-Pacific and Rest of the World

9. VECTOR AND GENE THERAPY MANUFACTURERS IN NORTH AMERICA
9.1. Chapter Overview
9.2. Advanced BioScience Laboratories
9.2.1. Company Overview
9.2.2. Manufacturing Facilities
9.2.3. Recent Developments and Future Outlook

9.3. Aldevron
9.3.1. Company Overview
9.3.2. Manufacturing Facilities
9.3.3. Manufacturing Experience
9.3.4. Recent Developments and Future Outlook

9.4. Audentes Therapeutics
9.4.1. Company Overview
9.4.2. Manufacturing Facilities
9.4.3. Recent Developments and Future Outlook

9.5. BioReliance / SAFC Commercial (Merck KGaA)
9.5.1. Company Overview
9.5.2. Financial Information
9.5.3. Vector Manufacturing Technology Portfolio
9.5.4. Manufacturing Facilities
9.5.5. Recent Developments and Future Outlook

9.6. bluebird bio
9.6.1. Company Overview
9.6.2. Financial Information
9.6.3. Manufacturing Facilities
9.6.4. Manufacturing Experience
9.6.5. Recent Development and Future Outlook

9.7. Brammer Bio
9.7.1. Company Overview
9.7.2. Manufacturing Facilities
9.7.3. Manufacturing Experience
9.7.4. Recent Developments and Future Outlook

9.8. Emergent BioSolutions
9.8.1. Company Overview
9.8.2. Financial Information
9.8.3. Manufacturing Facilities
9.8.4. Recent Developments and Future Outlook

9.9. FUJIFILM Diosynth Biotechnologies
9.9.1. Company Overview
9.9.2. Financial Information
9.9.3. Manufacturing Facilities
9.9.4. Manufacturing Experience
9.9.5. Recent Developments and Future Outlook

9.1 MeiraGTx
9.10.1. Company Overview
9.10.2. Manufacturing Facilities
9.10.3. Recent Developments and Future Outlook

9.11. Other Companies
9.11.1. MassBiologics
9.11.1.1. Company Overview
9.11.1.2. Manufacturing Facilities
9.11.1.3. Recent Developments and Future Outlook

9.11.2. Spark Therapeutics
9.11.2.1. Company Overview
9.11.2.2. Financial Information
9.11.2.3. Manufacturing Facilities
9.11.2.4. Vector Manufacturing Technology Portfolio
9.11.2.5. Manufacturing Experience
9.11.2.6. Recent Developments and Future Outlook

9.11.3. Vigene Biosciences
9.11.3.1. Company Overview
9.11.3.2. Manufacturing Facilities
9.11.3.3. Vector Manufacturing Technology Portfolio
9.11.3.4. Manufacturing Experience
9.11.3.5. Recent Developments and Future Outlook

10. VECTOR AND GENE THERAPY MANUFACTURERS IN EUROPE
10.1. Chapter Overview
10.2. Biovian
10.2.1. Company Overview
10.2.2. Manufacturing Facilities
10.2.3. Recent Developments and Future Outlook

10.3. Centre for Process Innovation
10.3.1. Company Overview
10.3.2. Manufacturing Facilities 
10.3.3. Recent Developments and Future Outlook

10.4. Cobra Biologics
10.4.1. Company Overview
10.4.2. Manufacturing Facilities
10.4.3. Vector Manufacturing Technology Portfolio
10.4.4. Manufacturing Experience
10.4.5. Recent Developments and Future Outlook

10.5. FinVector
10.5.1. Company Overview
10.5.2. Manufacturing Facilities
10.5.3. Vector Manufacturing Technology Portfolio
10.5.4. Manufacturing Experience
10.5.5. Recent Developments and Future Outlook

10.6. Kaneka Eurogentec
10.6.1. Company Overview
10.6.2. Manufacturing Facilities
10.6.3. Manufacturing Experience
10.6.4. Recent Developments and Future Outlook

10.7. Lonza
10.7.1. Company Overview
10.7.2. Financial Information
10.7.3. Vector Manufacturing Technology Portfolio
10.7.4. Manufacturing Facilities
10.7.5. Recent Developments and Future Outlook

10.8. MolMed
10.8.1. Company Overview
10.8.2. Financial Information
10.8.3. Manufacturing Facilities
10.8.4. Recent Developments and Future Outlook

10.9. Novasep
10.9.1. Company Overview
10.9.2. Financial Information
10.9.3. Manufacturing Facilities
10.9.4. Manufacturing Experience
10.9.5. Recent Developments and Future Outlook

10.10. Orchard Therapeutics
10.10.1. Company Overview
10.10.2. Manufacturing Facilities
10.10.3 Recent Developments and Future Outlook

10.11. Oxford BioMedica
10.11.1. Company Overview
10.11.2. Financial Information
10.11.3. Manufacturing Facilities
10.11.4. Vector Manufacturing Technology Portfolio
10.11.5. Manufacturing Experience
10.11.6. Recent Developments and Future Outlook

10.12. Richter-Helm
10.12.1. Company Overview
10.12.2. Manufacturing Facilities
10.12.3. Recent Developments and Future Outlook

10.13. Sanofi (CEPiA, Sanofi Pasteur, Genzyme)
10.13.1. Company Overview
10.13.2. Financial Information
10.13.3. Manufacturing Facilities
10.13.4. Recent Developments and Future Outlook

10.14. uniQure
10.14.1. Company Overview
10.14.2. Financial Information
10.14.3. Manufacturing Facilities
10.14.4. Vector Manufacturing Technology Portfolio
10.14.5. Recent Developments and Future Outlook

10.15. Vibalogics
10.15.1. Company Overview
10.15.2. Manufacturing Facilities
10.15.3. Recent Developments and Future Outlook

10.16. VIVEbiotech
10.16.1. Company Overview
10.16.2. Vector Manufacturing Technology Portfolio
10.16.3. Manufacturing Facilities
10.16.4. Recent Developments and Future Outlook

10.17. Other Companies
10.17.1. Cell and Gene Therapy Catapult
10.17.1.1. Company Overview
10.17.1.2. Manufacturing Facilities
10.17.1.3. Recent Developments and Future Outlook

11. VECTOR AND GENE THERAPY MANUFACTURERS IN ASIA-PACIFIC
11.1. Chapter Overview
11.2. Wuxi AppTec
11.2.1. Company Overview
11.2.2. Financial Information
11.2.3. Manufacturing Facilities
11.2.4. Manufacturing Experience
11.2.5. Recent Developments and Future Outlook
11.3. Other Key Players

12. RECENT PARTNERSHIPS
12.1. Chapter Overview
12.2. Partnership Models
12.3. Vector and Gene Therapy Manufacturing: Recent Partnerships
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Scale of Production
12.3.4. Analysis by Type of Vector
12.3.5. Analysis by Therapeutic Area
12.3.6. Most Active Players: Analysis by Number of Partnerships

12.3.7. Geographical Analysis
12.3.7.1. Intercontinental and Intracontinental Agreements
12.4. Other Collaborations

13. RECENT EXPANSIONS
13.1. Chapter Overview
13.2. Expansions Models
13.3. Vector and Gene Therapy Manufacturing: Recent Expansions
13.3.1. Analysis by Year of Expansion
13.3.2. Analysis by Type of Expansion
13.3.3. Analysis by Amount Invested by Key Players
13.3.4. Analysis by Scale of Production
13.3.5. Analysis by Type of Vector
13.3.6. Analysis by Application Area
13.3.7. Most Active Players: Analysis by Number of Expansions

13.3.8. Geographical Analysis
13.3.8.1. Analysis by Location of Expansion Project

14. STRATEGIC PARTNER ANALYSIS
14.1. Chapter Overview
14.2. Strategic Partner Analysis: Viral Vector based Therapy Developers
14.3. Methodology and Key Parameters
14.3.1. Opportunities for AAV Vector- based Therapy Developers
14.3.1.1. Most Likely Partners
14.3.1.2. Likely Partners
14.3.1.3. Less Likely Partners
14.3.1.4. Least Likely Partners

14.3.2. Opportunities for Adenoviral Vector based Therapy Developers
14.3.2.1. Most Likely Partners
14.3.2.2. Likely Partners
14.3.2.3. Less Likely Partners
14.3.2.4. Least Likely Partners

14.3.3. Opportunities for Lentiviral Vector based Therapy Developers
14.3.3.1. Most Likely Partners
14.3.3.2. Likely Partners
14.3.3.3. Less Likely Partners
14.3.3.4. Least Likely Partners

14.3.4. Opportunities for Retroviral Vector based Therapy Developers
14.3.4.1. Most Likely Partners
14.3.4.2. Likely Partners
14.3.4.3. Less Likely Partners
14.3.4.4. Least Likely Partners

14.3.5. Opportunities for Other Viral Vector based Therapy Developers
14.3.5.1. Most Likely Partners
14.3.5.2. Likely Partners
14.3.5.3. Less Likely Partners
14.3.5.4. Least Likely Partners

14.4. Strategic Partner Analysis: Viral Vector based Purification Product Developers
14.5. Methodology and Key Parameters
14.5.1. Opportunities for AAV based Purification Product Developers
14.5.1.1. Most Likely Partners
14.5.1.2. Likely Partners

14.5.2. Opportunities for Adenoviral Vector based Purification Product Developers
14.5.2.1. Most Likely Partners
14.5.2.2. Likely Partners

14.5.3. Opportunities for Lentiviral Vector based Purification Product Developers
14.5.3.1. Most Likely Partners
14.5.3.2. Likely Partners

14.5.4. Opportunities for Retroviral Vector based Purification Product Developers
14.5.4.1. Most Likely Partners
14.5.4.2. Likely Partners

14.5.5. Opportunities for Other Viral Vector based Purification Product Developers
14.5.5.1. Most Likely Partners
14.5.5.2. Likely Partners

15. EMERGING VECTORS
15.1. Chapter Overview
15.1.1. Alphavirus based Vectors
15.1.2. Anc80 based Vectors
15.1.3. Bifidobacterium longum based Vectors
15.1.4. Cytomegalovirus based Vectors
15.1.5. Listeria monocytogenes based Vectors
15.1.6. Minicircle DNA based Vectors
15.1.7. Myxoma Virus based Vectors
15.1.8. Self-Complementary Vectors
15.1.9. Sendai Virus based Vectors
15.1.10. Sleeping Beauty Transposons
15.1.11. Vaccinia Virus and Modified Vaccinia Ankara based Vectors

16. KEY INSIGHTS
16.1. Chapter Overview
16.2. Vector and Gene Therapy Manufacturers: Analysis by Purpose of Manufacturing, Type of Vector Manufactured and Scale of Operation
16.3. Vector and Gene Therapy Manufacturers: Analysis by Company Size and Type of Vector Manufactured
16.4. Vector and Gene Therapy Manufacturers: Prominent Geographical Hubs by Type of Organization
16.4.1. Contract Manufacturing Organizations
16.4.2. In-House Manufacturers

16.5. Vector and Gene Therapy Manufacturers: Analysis by Location of Manufacturing Facilities and Type of Vector Manufactured
16.5.1. AAV Vector Manufacturers
16.5.2. Adenoviral Vector Manufacturers
16.5.3. Lentiviral Vector Manufacturers
16.5.4. Retroviral Vector Manufacturers
16.5.5. Plasmid DNA Manufacturers

17. COST PRICE ANALYSIS
17.1. Chapter Overview
17.2. Factors Contributing to High Price of Viral Vector and Plasmid DNA based Therapies
17.3. Viral Vector and Plasmid DNA based Therapies: Pricing Models 
17.3.1. On the Basis of Expert Opinions
17.3.2. On the Basis of Manufacturing Cost
17.3.2.1. On the Basis of Technology Used
17.3.2.2. On the Basis of Scale of Manufacturing
17.3.2.3. On the Basis of Type of Client
17.3.3. Prices of Different Types of Vectors
17.4. Concluding Remarks

18. CAPACITY ANALYSIS
18.1. Chapter Overview
18.2. Methodology and Key Assumptions
18.2. Global Installed Viral Vector and Gene Therapy Manufacturing Capacity
18.3. Global Installed Viral Vector Manufacturing Capacity
18.3.1. Analysis by Company Size
18.3.2. Analysis by Scale of Production
18.3.3. Analysis by Location of Manufacturing Facilities

18.4. Global Installed Plasmid DNA Manufacturing Capacity
18.4.1. Analysis by Company Size
18.4.2. Analysis by Scale of Production
18.4.3. Analysis by Location of Manufacturing Facilities
18.4. Concluding Remarks

19. DEMAND ANALYSIS
19.1. Chapter Overview
19.2. Assumptions and Methodology
19.3. Global Clinical Demand for Viral Vectors and Plasmid DNA, 2021-2030
19.3.1. Analysis by Type of Vector
19.3.2. Analysis by Type of Therapy
19.3.3. Analysis by Therapeutic Area
19.3.4. Analysis by Geographical Location

19.4. Global Commercial Demand for Viral Vectors and Plasmid DNA, 2021-2030
19.4.1. Analysis by Type of Vector
19.4.2. Analysis by Type of Therapy
19.4.3. Analysis by Therapeutic Area
19.4.4. Analysis by Geographical Location

19.5. Demand and Supply Analysis
19.5.1. Scenario 1
19.5.2. Scenario 2
19.5.3. Scenario 3

20. MARKET SIZING AND OPPORTUNITY ANALYSIS
20.1. Chapter Overview
20.2. Scope of the Forecast
20.3. Forecast Methodology 
20.4. Input Tables and Key Assumptions
20.5. Global Viral Vector and Plasmid DNA Manufacturing Market, 2021-2030
20.5.1. Viral Vector and Plasmid DNA Manufacturing Market, 2021-2030: Distribution by Type of Vector Manufactured
20.5.1.1. Viral Vector and Plasmid DNA Manufacturing Market, 2021-2030: Market Attractiveness by Purpose of Manufacturing
20.5.2. Viral Vector and Plasmid DNA Manufacturing Market, 2021-2030: Distribution by Scale of Operation
20.5.3. Viral Vector and Plasmid DNA Manufacturing Market, 2021-2030: Distribution by Type of Vector Manufactured
20.5.4. Viral Vector and Plasmid DNA Manufacturing Market, 2021-2030: Distribution by Therapeutic Area
20.5.5. Viral Vector and Plasmid DNA Manufacturing Market, 2021-2030: Distribution by Application Area
20.5.6. Viral Vector and Plasmid DNA Manufacturing Market, 2021-2030: Distribution by Key Geographical Regions

20.6. Current and Future Market Opportunity from Commercial Products
20.6.1. Viral Vector and Plasmid DNA Manufacturing Market for Commercial Products, 2021-2030: Distribution by Type of Vector Manufactured
20.6.2. Viral Vector and Plasmid DNA Manufacturing Market for Commercial Products, 2021-2030: Distribution by Therapeutic Area
20.6.3. Viral Vector and Plasmid DNA Manufacturing Market for Commercial Products, 2021-2030: Distribution by Application Area
20.6.4. Viral Vector and Plasmid DNA Manufacturing Market for Commercial Products, 2021-2030: Distribution by Key Geographical Regions
20.6.4.1. AAV Vectors
20.6.4.1.1. AAV Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Therapeutic Area
20.6.4.1.2. AAV Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Application Area
20.6.4.1.3. AAV Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Key Geographical Regions

20.6.4.2. Adenoviral Vectors
20.6.4.2.1. Adenoviral Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Therapeutic Area
20.6.4.2.2. Adenoviral Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Application Area
20.6.4.2.3. Adenoviral Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Key Geographical Regions

20.6.4.3. Lentiviral Vectors
20.6.4.3.1. Lentiviral Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Therapeutic Area
20.6.4.3.2. Lentiviral Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Application Area
20.6.4.3.3. Lentiviral Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Key Geographical Regions

20.6.4.4. Retroviral Vectors
20.6.4.4.1. Retroviral Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Therapeutic Area
20.6.4.4.2. Retroviral Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Application Area
20.6.4.4.3. Retroviral Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Key Geographical Regions

20.6.4.5. Plasmid DNA
20.6.4.5.1. Plasmid DNA Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Therapeutic Area
20.6.4.5.2. Plasmid DNA Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Application Area
20.6.4.5.3. Plasmid DNA Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Key Geographical Regions

20.7. Current and Future Market Opportunity for Clinical Candidates 
20.7.1. Viral Vector and Plasmid DNA Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Phase of Development
20.7.2. Viral Vector and Plasmid DNA Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Type of Vector Manufactured
20.7.3. Viral Vector and Plasmid DNA Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Application Area

20.7.4. Viral Vector and Plasmid DNA Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Key Geographical Regions
20.7.4.1. AAV Vectors
20.7.4.1.1. AAV Vector Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Phase of Development
20.7.4.1.2. AAV Vector Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Application Area
20.7.4.1.3. AAV Vector Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Key Geographical Regions

20.7.4.2. Adenoviral Vectors
20.7.4.2.1. Adenoviral Vector Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Phase of Development
20.7.4.2.2. Adenoviral Vector Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Application Area
20.7.4.2.3. Adenoviral Vector Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Key Geographical Regions

20.7.4.3. Lentiviral Vectors
20.7.4.3.1. Lentiviral Vector Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Phase of Development
20.7.4.3.2. Lentiviral Vector Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Application Area
20.7.4.3.3. Lentiviral Vector Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Key Geographical Regions

20.7.4.4. Retroviral Vectors
20.7.4.4.1. Retroviral Vector Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Phase of Development
20.7.4.4.2. Retroviral Vector Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Application Area
20.7.4.4.3. Retroviral Vector Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Key Geographical Regions

20.7.4.5. Plasmid DNA
20.7.4.5.1. Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Phase of Development
20.7.4.5.2. Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Application Area
20.7.4.5.3. Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Key Geographical Regions

20.8. Current and Future Market Opportunity from Preclinical Candidates
20.8.1. Viral Vector and Plasmid DNA Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Type of Vector Manufactured
20.8.2. Viral Vector and Plasmid DNA Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Type of Animal Model Used
20.8.3. Viral Vector and Plasmid DNA Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Therapeutic Area
20.8.4. Viral Vector and Plasmid DNA Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Application Area
20.8.5. Viral Vector and Plasmid DNA Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Key Geographical Regions

20.8.5.1. AAV Vectors
20.8.5.1.1. AAV Vector Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Type of Animal Model Used
20.8.5.1.2. AAV Vector Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Application Area
20.8.5.1.3. AAV Vector Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Key Geographical Regions

20.8.5.2. Adenoviral Vectors
20.8.5.2.1. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Type of Animal Model Used
20.8.5.2.2. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Application Area
20.8.5.2.3. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Key Geographical Regions

20.8.5.3. Lentiviral Vectors
16.8.5.3.1. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Type of Animal Model Used
20.8.5.3.2. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Application Area
20.8.5.3.3. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Key Geographical Regions

20.8.5.4. Retroviral Vectors
20.8.5.4.1. Retroviral Vector Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Type of Animal Model Used
20.8.5.4.2. Retroviral Vector Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Application Area
20.8.5.4.3. Retroviral Vector Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Key Geographical Regions

20.8.5.5. Plasmid DNA
20.8.5.5.1. Plasmid DNA Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Type of Animal Model Used
20.8.5.5.2. Plasmid DNA Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Application Area
20.8.5.5.3. Plasmid DNA Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Key Geographical Regions

20.9 Current and Future Market opportunity from Vector-Based Vaccines
20.9.1. Viral Vector and Plasmid DNA Manufacturing Market for Vector Based Vaccines, 2021-2030: Distribution by Scale of Operation
20.9.2. Viral Vector and Plasmid DNA Manufacturing Market for Vector Based Vaccines, 2021-2030: Distribution by Type of Vector Manufactured
20.9.3. Viral Vector and Plasmid DNA Manufacturing Market for Vector Based Vaccines, 2021-2030: Distribution by Therapeutic Area
20.9.4. Viral Vector and Plasmid DNA Manufacturing Market for Vector Based Vaccines, 2021-2030: Distribution by Key Geographical Regions

21. IMPACT OF COVID-19 PANDEMIC ON THE VECTOR AND GENE THERAPY MANUFACTURING MARKET
21.1 Chapter Overview
21.2. Current Opinions and Recuperative Initiatives of Key Players
21.2.1. GE Healthcare (Cytiva)
21.2.2. Lonza
21.2.3. Pfizer
21.2.4. WuXi AppTec

21.3. Impact on Vector and Gene Therapy Manufacturing Market
21.4. Recuperative Strategies for Contract Service Providers
21.4.1. Strategies for Implementation in the Short / Mid Term
21.4.2. Strategies for Implementation in the Long Term

22. KEY DRIVERS AND CHALLENGES
22.1. Chapter Overview
22.2. Viral Vector and Plasmid DNA Manufacturing Market: Key Drivers and Challenges
22.2.1. AAV Vectors
22.2.2. Adenoviral Vectors
22.2.3. Lentiviral Vectors
22.2.4. Retroviral Vectors
22.2.5. Plasmid DNA
22.3. Concluding Remarks

23. SURVEY ANALYSIS
23.1. Chapter Overview
23.2. Analysis by Seniority Level of Respondents
23.3. Analysis by Purpose of Production
23.4. Analysis by Scale of Production 
23.5. Analysis by Type of Vector Manufactured

24. CONCLUDING REMARKS

25. EXECUTIVE INSIGHTS
25.1. Chapter Overview
25.2. Batavia Biosciences
25.2.1. Company Snapshot 
25.2.2. Interview Transcript: Menzo Havenga, Chief Executive Officer and President

25.3. CEVEC Pharmaceuticals
25.3.1. Company Snapshot 
25.3.2. Interview Transcript: Nicole Faust, Chief Executive Officer & Chief Scientific Officer

25.4. Vigene Biosciences
25.4.1. Company Snapshot 
25.4.2. Interview Transcript: Jeffrey Hung, Chief Commercial Officer

25.5. Delphi Genetics
25.5.1. Company Snapshot 
25.5.2. Interview Transcript: Cedric Szpirer, Founder, Executive & Scientific Director

25.6. Clean Cells
25.6.1. Company Snapshot 
25.6.2. Interview Transcript: Olivier Boisteau, Co-Founder / President, Laurent Ciavatti, Ex-Business Development Manager and Xavier Leclerc, Head of Gene Therapy

25.7. Novasep
25.7.1. Company Snapshot 
25.7.2. Interview Transcript: Alain Lamproye, Ex-President of Biopharma Business Unit

25.8. Amsterdam BioTherapeutics Unit (AmBTU)
25.8.1. Organization Snapshot 
25.8.2. Interview Transcript: Joost van den Berg, Ex-Director

25.9. MGH Viral Vector Development Facility, Massachusetts General Hospital
25.9.1. Organization Snapshot 
25.9.2. Interview Transcript: Bakhos A Tannous, Director

25.10. Translational Vector Core, University of Nantes
25.10.1. Organization Snapshot
25.10.2. Interview Transcript: Eduard Ayuso, DVM, PhD, Scientific Director

25.11. CJ PARTNERS
25.11.1. Company Snapshot
25.11.2. Interview Transcript: Colin Lee Novick, Managing Director

25.12. ACGT
25.12.1. Company Snapshot
25.12.2. Interview Transcript: Semyon Rubinchik, Scientific Director

25.13. Richter-Helm
25.13.1. Company Snapshot
25.13.2. Interview Transcript: Astrid Brammer, Senior Manager Business Development

25.14. Plasmid Factory
25.14.1. Company Snapshot
25.14.2. Interview Transcript: Marco Schmeer, Project Manager and Tatjana Buchholz, Ex-Marketing Manager

25.15. Waisman Biomanufacturing
25.15.1. Company Snapshot
25.15.2. Interview Transcript: Brian M Dattilo, Business Development Manager

25.16. EFS-West Biotherapy
25.16.1. Company Snapshot
25.16.2. Interview Transcript: Beatrice Araud, ATMP Key Account Manager

25.17. GEG Tech
25.17.1. Company Snapshot
25.17.2. Interview Transcript: Nicolas Grandchamp, R&D Leader

26. APPENDIX I: TABULATED DATA

27. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

List Of Figures

Figure 3.1 Viral and Non-Viral Techniques for Gene Transfer
Figure 3.2 Vector Production: Types of Manufacturers
Figure 3.3 Viral Vectors: Manufacturing Process
Figure 4.1 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Figure 4.2 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Figure 4.3 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Continent-wise)
Figure 4.4 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Countries-wise)
Figure 4.5 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Figure 4.6 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Viral Vector Manufacturing Facilities (Continent-wise )
Figure 4.7 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Viral Vector Manufacturing Facilities (Countries-wise )
Figure 4.8 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Purpose of Production and Company Size
Figure 4.9 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Production
Figure 4.10 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Vector Manufactured
Figure 4.11 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Figure 5.1 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Figure 5.2 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Figure 5.3 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Continents)
Figure 5.4 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Countries)
Figure 5.5 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Figure 5.6 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facilities (Continents)
Figure 5.7 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facilities (Countries)
Figure 5.8 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Purpose of Production
Figure 5.9 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Production
Figure 5.10 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Figure 6.1 Vector and Gene Therapy Manufacturers (Non-Industry Players): Cumulative Trend by Year of Establishment
Figure 6.2 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Vector Manufacturing Facilities (Continents)
Figure 6.3 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Vector Manufacturing Facilities (Countries)
Figure 6.4 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Purpose of Production and Location of Vector Manufacturing Facilities
Figure 6.5 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Scale of Production
Figure 6.6 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Vector Manufactured
Figure 6.7 Logo Landscape: Distribution by Scale of Production and Type of Vector Manufactured
Figure 6.8 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Application Area
Figure 7.1 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Technology
Figure 7.2 Vector and Gene Therapy Manufacturing Technologies: Distribution by Purpose of Technology
Figure 7.3 Vector and Gene Therapy Manufacturing Technologies: Distribution by Scale of Production
Figure 7.4 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Vector Manufactured
Figure 7.5 Vector and Gene Therapy Manufacturing Technologies: Distribution by Application Area
Figure 7.6 Most Active Players: Distribution by Type of Technology
Figure 8.1 Company Competitiveness Analysis: Distribution of Players based in North America (In-House Manufacturers)
Figure 8.2 Company Competitiveness Analysis: Distribution of Players based in Europe (In-House Manufacturers)
Figure 8.3 Company Competitiveness Analysis: Distribution of Players based in Asia-Pacific and Rest of the World (In-House Manufacturers)
Figure 8.4 Company Competitiveness Analysis: Distribution of Players based in North America (Contract Manufacturing Organizations)
Figure 8.5 Company Competitiveness Analysis: Distribution of Players based in Europe (Contract Manufacturing Organizations)
Figure 8.6 Company Competitiveness Analysis: Distribution of Players based in Asia-Pacific and Rest of the World (Contract Manufacturing Organizations)
Figure 8.7 Company Competitiveness Analysis: Distribution of Players based in North America (Both In-House and Contract Manufacturing Organizations)
Figure 8.8 Company Competitiveness Analysis: Distribution of Players based in Europe (Both In-House and Contract Manufacturing Organizations)
Figure 8.9 Company Competitiveness Analysis: Distribution of Players based in Asia-Pacific and Rest of the World (Both In-House and Contract Manufacturing Organizations)
Figure 9.1 Merck KGaA: Annual Revenues, 2014 - H1 2020 (EUR Billion)
Figure 9.2 Merck KGaA: Annual Revenues by Business Sector, 2019 (EUR Billion)
Figure 9.3 H.A.V.E.: AAV Vector Manufacturing Technology
Figure 9.4 bluebird bio: Annual Revenues, 2014 - H1 2020 (USD Million)
Figure 9.5 Emergent BioSolutions: Annual Revenues, 2016 - 9M 2020 (USD Million)
Figure 9.6 FUJIFILM Holdings: Annual Revenues, 2013 - Q1 FY 2021 (JPY Billion)
Figure 9.7 FUJIFILM Holdings: Revenues by Business Divisions, FY 2020 (JPY Billion)
Figure 9.8 Spark Therapeutics: Annual Revenues, 2014 - 9M 2019 (USD Million)
Figure 10.1 Lonza: Annual Revenues, 2014 - H1 2020 (CHF Billion)
Figure 10.2 MolMed: Annual Revenues, 2013 - H1 2020 (EUR Million)
Figure 10.3 Novasep: Annual Revenues, 2013 - 10 M 2018 (EUR Million)
Figure 10.4 Novasep: Viral Vector Manufacturing Process
Figure 10.5 Oxford BioMedica: Annual Revenues, 2014 - H1 2020 (GBP Million)
Figure 10.6 Sanofi: Annual Revenues, 2014 - H1 2020 (EUR Billion)
Figure 10.7 uniQure: Annual Revenues, 2014 - H1 2020 (USD Million)
Figure 11.1 Wuxi AppTec: Annual Revenues, 2017 - H1 2020 (RMB Million)
Figure 12.1 Recent Partnerships: Cumulative Year-wise Trend, 2015 - 2020 (till September)
Figure 12.2 Recent Partnerships: Distribution by Type of Partnership, 2015 - 2020 (till September)
Figure 12.3 Recent Partnerships: Distribution by Type and Year of Partnership, 2015 - 2020 (till September)
Figure 12.4 Recent Partnerships: Distribution by Scale of Operation
Figure 12.5 Recent Partnerships: Distribution by Type of Vector(s)
Figure 12.6 Recent Partnerships: Distribution by Therapeutic Area
Figure 12.7 Most Active Players: Distribution by Number of Partnerships
Figure 12.8 Recent Partnerships: Geographical Analysis
Figure 12.9 Recent Partnerships: Intercontinental and Intracontinental Agreements
Figure 13.1 Recent Expansions: Cumulative Year-wise Trend, 2015 - 2020 (till September)
Figure 13.2 Recent Expansions: Distribution by Type of Expansion, 2015 - 2020 (till September)
Figure 13.3 Recent Expansions: Distribution by Type and Year of Expansion, 2015 - 2020 (till September)
Figure 13.4 Recent Expansions: Distribution of Amount Invested by Key Players
Figure 13.5 Recent Expansions: Distribution by Scale of Operation
Figure 13.6 Recent Expansions: Distribution by Type of Vector(s)
Figure 13.7 Recent Expansions: Distribution by Application Area
Figure 13.8 Most Active Players: Distribution by Number of Expansions
Figure 13.9 Recent Expansions: Intercontinental and Intracontinental Expansions
Figure 13.10 Recent Expansions: Distribution by Location of Expansion Project
Figure 16.1 Vector and Gene Therapy Manufacturers: Competitive Landscape by Purpose of Production, Type of Vector Manufactured and Scale of Operation
Figure 16.2 Vector and Gene Therapy Manufacturers: Logo Landscape by Company Size and Type of Vector Manufactured
Figure 16.3 Vector and Gene Therapy Contract Manufacturers: Distribution by Prominent Geographical Hubs
Figure 16.4 Vector and Gene Therapy In-House Manufacturers: Distribution by Prominent Geographical Hubs
Figure 16.5 AAV Vector Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 16.6 Adenoviral Vector Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 16.7 Lentiviral Vector Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 16.8 Retroviral Vector Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 16.9 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 17.1 Viral Vector and Plasmid DNA Cost Price Analysis: Vector Production Process and Relative Costs Involved
Figure 18.1 Global Installed Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Type of Vector Manufactured (in Liters)
Figure 18.2 Global Installed Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (in Liters)
Figure 18.3 Global Installed Viral Vector Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
Figure 18.4 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
Figure 18.5 Global Installed Viral Vector Manufacturing Capacity: Distribution by Company Size (in Liters)
Figure 18.6 Global Installed Viral Vector Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Figure 18.7 Global Installed Viral Vector Manufacturing Capacity: Distribution by Scale of Production (in Liters)
Figure 18.8 Global Installed Viral Vector Manufacturing Capacity: Distribution by Geographical Location of Viral Vector Manufacturing Facilities (in Liters)
Figure 18.9 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Company Size (in Liters)
Figure 18.10 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Figure 18.11 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Scale of Production
Figure 18.12 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Location of Plasmid DNA Manufacturing Facilities (in Liters)
Figure 19.1 Global Clinical Demand for Viral Vector and Plasmid DNA, 2021-2030 (Thousand Patients)
Figure 19.2 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector Manufactured (Thousand Patients)
Figure 19.3 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy (Thousand Patients)
Figure 19.4 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Therapeutic Area (Thousand Patients)
Figure 19.5 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location (Thousand Patients)
Figure 19.6 Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients)
Figure 19.7 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector Manufactured (Thousand Patients)
Figure 19.8 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy (Thousand Patients)
Figure 19.9 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Therapeutic Area (Thousand Patients)
Figure 19.10 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location (Thousand Patients)
Figure 19.11 Global Viral Vector Manufacturing: Demand and Supply (Scenario 1), 2021-2030
Figure 19.12 Global Viral Vector Manufacturing: Demand and Supply (Scenario 2), 2021-2030
Figure 19.13 Global Viral Vector Manufacturing: Demand and Supply (Scenario 3), 2021-2030
Figure 20.1 Viral Vector and Plasmid DNA Manufacturing Market, 2021-2030 (USD Million)
Figure 20.2 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Type of Vector Manufactured, 2021-2030 (USD Million)
Figure 20.3 Viral Vector and Plasmid DNA Manufacturing Market: Market Attractiveness Analysis by Type of Vector Manufactured, 2021-2030
Figure 20.4 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.5 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Therapeutic Area, 2021, 2025 and 2030 (USD Million)
Figure 20.6 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Scale of Operation, 2021-2030 (USD Million)
Figure 20.7 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Purpose of Production, 2021-2030 (USD Million)
Figure 20.8 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.9 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.10 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2021, 2025 and 2030 (USD Million)
Figure 20.11 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2021, 2025 and 2030 (USD Million)
Figure 20.12 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Type of Vector Manufactured, 2021, 2025 and 2030 (USD Million)
Figure 20.13 AAV Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.14 AAV Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 20.15 AAV Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.16 Adenoviral Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.17 Adenoviral Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 20.18 Adenoviral Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.19 Lentiviral Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.20 Lentiviral Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 20.21 Lentiviral Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.22 Retroviral Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.23 Retroviral Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 20.24 Retroviral Vector Manufacturing Market for Commercial Product: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.25 Plasmid DNA Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.26 Plasmid DNA Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 20.27 Plasmid DNA Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.28 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.29 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2021-2030 (USD Million)
Figure 20.30 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2021, 2025 and 2030 (USD Million)
Figure 20.31 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Type of Vector Manufactured, 2021-2030 (USD Million)
Figure 20.32 AAV Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.33 AAV Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2021-2030 (USD Million)
Figure 20.34 AAV Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.35 Adenoviral Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.36 Adenoviral Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2021-2030 (USD Million)
Figure 20.37 Adenoviral Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.38 Lentiviral Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.39 Lentiviral Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2021-2030 (USD Million)
Figure 20.40 Lentiviral Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.41 Retroviral Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.42 Retroviral Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2021-2030 (USD Million)
Figure 20.43 Retroviral Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.44 Plasmid DNA Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.45 Plasmid DNA Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2021-2030 (USD Million)
Figure 20.46 Plasmid DNA Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.47 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.48 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Therapeutic Area, 2021, 2025 and 2030 (USD Million)
Figure 20.49 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Animal Model Used, 2021-2030 (USD Million)
Figure 20.50 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2021, 2025 and 2030 (USD Million)
Figure 20.51 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Type of Vector Manufactured, 2021-2030 (USD Million)
Figure 20.52 AAV Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.53 AAV Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2021-2030 (USD Million)
Figure 20.54 AAV Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.55 Adenoviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.56 Adenoviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2021-2030 (USD Million)
Figure 20.57 Adenoviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.58 Lentiviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.59 Lentiviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2021-2030 (USD Million)
Figure 20.60 Lentiviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.61 Retroviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.62 Retroviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2021-2030 (USD Million)
Figure 20.63 Retroviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.64 Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.65 Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2021-2030 (USD Million)
Figure 20.66 Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.67 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Type of Vector Manufactured, 2021-2030 (USD Million)
Figure 20.68 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Scale of Operation, 2021-2030 (USD Million)
Figure 20.69 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 20.70 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 21.1 Viral Vectors and Plasmid DNA Manufacturing Market: COVID-19 Impact Informed Scenario, 2021-2030 (USD Billion)
Figure 22.1 Key Drivers and Challenges: AAV Vectors
Figure 22.2 Key Drivers and Challenges: Adenoviral Vectors
Figure 22.3 Key Drivers and Challenges: Lentiviral Vectors
Figure 22.4 Key Drivers and Challenges: Retroviral Vectors
Figure 22.5 Key Drivers and Challenges: Plasmid DNA
Figure 23.1 Survey Analysis: Distribution by Seniority Level of Respondents
Figure 23.2 Survey Analysis: Distribution by Scale of Production
Figure 23.3 Survey Analysis: Distribution by Type of Vector Manufactured
Figure 24.1 Viral Vectors and Plasmid DNA Market: Distribution by Type of Vector Manufactured, 2021, 2025 and 2030 (USD Million)

List of Tables

Table 3.1 Key Features of Viral Vectors
Table 3.2 Key Features of Small-scale Cell Culture Systems
Table 4.1 Viral Vector and Gene Therapy Manufacturers: List of Industry Players
Table 4.2 Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Location of Viral Vector Manufacturing Facilities, Scale of Production and Purpose of Production
Table 4.3 Heat Map: Information on Location of Headquarters and Scale of Production
Table 4.4 Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Type of Viral Vector Manufactured
Table 4.5 Heat Map: Information on Scale of Production and Type of Viral Vector Manufactured
Table 4.6. Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Application Area
Table 4.7. Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Production Capacity
Table 5.1 Plasmid DNA and Gene Therapy Manufacturers: List of Industry Players
Table 5.2 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Company Size and Location of Headquarters
Table 5.3 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Location of Plasmid DNA Manufacturing Facilities, Scale of Production and Purpose of Production
Table 5.4 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Application Area
Table 5.5 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Production Capacity
Table 6.1 Vector and Gene Therapy Manufacturers: List of Non-Industry Players
Table 6.2 Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Scale of Production
Table 6.3 Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Type of Vector Manufactured
Table 6.4 Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Application Area
Table 7.1 Vector and Gene Therapy Manufacturing Technologies: List of Technology Platforms
Table 9.1 Vector and Gene Therapy Production in North America: List of Profiled Companies
Table 9.2 Advanced BioScience Laboratories: Recent Developments and Future Outlook
Table 9.3 Aldevron Plasmid DNA: QC Assays
Table 9.4 Aldevron: Recent Developments and Future Outlook
Table 9.5 Audentes Therapeutics: Recent Developments and Future Outlook
Table 9.6 BioReliance / SAFC Commercial (Merck KGaA): Recent Developments and Future Outlook
Table 9.7 bluebird bio: Recent Developments and Future Outlook
Table 9.8 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 9.9 FUJIFILM Diosynth Biotechnologies: Recent Developments and Future Outlook
Table 9.10 MeiraGTx: Recent Developments and Future Outlook
Table 9.11 MassBiologics: Recent Developments and Future Outlook
Table 9.12 Spark Therapeutics: Recent Developments and Future Outlook
Table 9.13 Vigene Biosciences: Recent Developments and Future Outlook
Table 10.1 Vector and Gene Therapy Production in Europe: List of Players Profiled
Table 10.2 Biovian: Recent Developments and Future Outlook
Table 10.3 Centre for Process Innovation: Recent Developments and Future Outlook
Table 10.4 Cobra Biologics: Recent Developments and Future Outlook
Table 10.5 FinVector: Recent Developments and Future Outlook
Table 10.6 Kaneka Eurogentec: Recent Developments and Future Outlook
Table 10.7 Lonza: Recent Developments and Future Outlook
Table 10.8 MolMed: Recent Developments and Future Outlook
Table 10.9 Novasep: Manufacturing Experience
Table 10.10 Novasep: Recent Developments Future Outlook
Table 10.11 Orchard Therapeutics: Recent Developments Future Outlook
Table 10.12 Oxford BioMedica: Recent Developments and Future Outlook
Table 10.13 Richter-Helm: Recent Developments and Future Outlook
Table 10.14 Sanofi: Recent Developments and Future Outlook
Table 10.15 uniQure: Recent Developments and Future Outlook
Table 10.16 Vibalogics: Recent Developments and Future Outlook
Table 10.17 VIVEbiotech: Recent Developments and Future Outlook
Table 10.18 Cell and Gene Therapy Catapult: Recent Developments and Future Outlook
Table 11.1 Wuxi AppTec: Recent Developments and Future Outlook
Table 11.2 List of Other Key Players Based in Asia Pacific
Table 12.1 Vector and Gene Therapy Manufacturing: List of Recent Partnerships, 2015-2020 (till September)
Table 12.2 Vector and Gene Therapy Manufacturing: List of Other Partnerships, 2015-2020 (till September)
Table 13.1 Vector and Gene Therapy Manufacturing: List of Recent Expansions, 2015-2020 (till September)
Table 13.2 Vector and Gene Therapy Manufacturing: Information on Scale of Production, Type of Vector Manufactured and Application Area, 2015-2020 (till September)
Table 14.1 AAV Vector-based Therapy Developers: Most Likely Partners
Table 14.2 AAV Vector-based Therapy Developers: Likely Partners
Table 14.3 AAV Vector-based Therapy Developers: Less Likely Partners
Table 14.4 AAV Vector-based Therapy Developers: Least Likely Partners
Table 14.5 Adenoviral Vector-based Therapy Developers: Most Likely Partners
Table 14.6 Adenoviral Vector-based Therapy Developers: Likely Partners
Table 14.7 Adenoviral Vector-based Therapy Developers: Less Likely Partners
Table 14.8 Adenoviral Vector-based Therapy Developers: Least Likely Partners
Table 14.9 Lentiviral Vector-based Therapy Developers: Most Likely Partners
Table 14.10 Lentiviral Vector-based Therapy Developers: Likely Partners
Table 14.11 Lentiviral Vector-based Therapy Developers: Less Likely Partners
Table 14.12 Lentiviral Vector-based Therapy Developers: Least Likely Partners
Table 14.13 Retroviral Vector-based Therapy Developers: Most Likely Partners
Table 14.14 Retroviral Vector-based Therapy Developers: Likely Partners
Table 14.15 Retroviral Vector-based Therapy Developers: Less Likely Partners
Table 14.16 Retroviral Vector-based Therapy Developers: Least Likely Partners
Table 14.17 Other Viral Vector-based Therapy Developers: Most Likely Partners
Table 14.18 Other Viral Vector-based Therapy Developers: Likely Partners
Table 14.19 Other Viral Vector-based Therapy Developers: Less Likely Partners
Table 14.20 Other Viral Vector-based Therapy Developers: Least Likely Partners
Table 14.21 AAV Vector Purification Product Developers: Most Likely Partners
Table 14.22 AAV Vector Purification Product Developers: Likely Partners
Table 14.23 Adenoviral Vector Purification Product Developers: Most Likely Partners
Table 14.24 Adenoviral Vector Purification Product Developers: Likely Partners
Table 14.25 Lentiviral Vector Purification Product Developers: Most Likely Partners
Table 14.26 Lentiviral Vector Purification Product Developers: Likely Partners
Table 14.27 Retroviral Vector Purification Product Developers: Most Likely Partners
Table 14.28 Retroviral Vector Purification Product Developers: Likely Partners
Table 14.29 Other Viral Vector Purification Product Developers: Most Likely Partners
Table 14.30 Other Viral Vector Purification Product Developers: Likely Partners
Table 17.1 Viral Vector and Plasmid DNA Cost Price Analysis: Expert Opinions / Primary Research
Table 17.2 Viral Vector and Plasmid DNA: Prices of Vectors
Table 18.1 Global Installed Viral Vector Manufacturing Capacity: Sample Data Set
Table 18.2 Global Installed Plasmid DNA Manufacturing Capacity: Sample Data Set
Table 18.3 Global Installed Viral Vector Manufacturing Capacity: Distribution by Company Size
Table 18.4 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Company Size
Table 19.1. Global Viral Vectors Manufacturing Annual Demand, 2021-2030 (1020 vg)
Table 19.2 Global Viral Vectors Manufacturing Annual Supply (Scenario 1), 2021-2030 (1020 vg)
Table 19.3 Global Viral Vector Manufacturing: Annual Supply (Scenario 2), 2021-2030 (1020 vg)
Table 19.4 Global Viral Vector Manufacturing: Annual Supply (Scenario 3), 2021-2030 (1020 vg)
Table 20.1 Viral Vector and Plasmid DNA: Active Clinical Studies (Vector-Based Cell and Gene Therapies)
Table 20.2 Viral Vector and Plasmid DNA: Distribution by Patients Enrolled in the Active Clinical Studies (Vector-Based Cell and Gene Therapies)
Table 20.3 Viral Vector and Plasmid DNA: Number of Active Clinical Trials (Vector-Based Cell and Gene Therapies), 2021-2030
Table 20.4 Viral Vector and Plasmid DNA: Number of Patients Enrolled in Active Clinical Trials (Vector-Based Cell and Gene Therapies), 2021-2030
Table 20.5 Viral Vector and Plasmid DNA: Approved / Late-Stage Cell and Gene Therapies
Table 23.1 Survey Response: Overview of the Participating Companies / Organizations
Table 23.2 Survey Response: Seniority Level of Respondents
Table 23.3 Survey Response: Type of Vector
Table 23.4 Survey Response: Scale of Production
Table 23.5 Survey Response: Vector Stabilization Technology
Table 23.6 Survey Response: Purpose of Production (In-house Production versus Contract Services)
Table 25.1 Batavia Biosciences: Key Highlights
Table 25.2 CEVEC Pharmaceuticals: Key Highlights
Table 25.3 Vigene Biosciences: Key Highlights
Table 25.4 Delphi Genetics: Key Highlights
Table 25.5 Clean Cells: Key Highlights
Table 25.6 Novasep: Key Highlights
Table 25.7 Amsterdam BioTherapeutics Unit (AmBTU): Key Highlights
Table 25.8 MGH Viral Vector Development Facility, Massachusetts General Hospital: Key Highlights
Table 25.9 Translational Vector Core, University of Nantes: Key Highlights
Table 25.10 CJ PARTNERS: Key Highlights
Table 25.11 ACGT: Key Highlights
Table 25.12 Richter-Helm: Key Highlights
Table 25.13 Plasmid Factory: Key Highlights
Table 25.14 Waisman Biomanufacturing: Key Highlights
Table 25.15 EFS-West Biotherapy: Key Highlights
Table 25.16 GEG Tech: Key Highlights
Table 26.1 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Table 26.2 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Table 26.3 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Continents-wise)
Table 26.4 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Countries-wise)
Table 26.5 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Table 26.6 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Viral Vector Manufacturing Facilities (Continents-wise)
Table 26.7 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Viral Vector Manufacturing Facilities (Countries-wise)
Table 26.8 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Purpose of Production and Company Size
Table 26.9 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Production
Table 26.10 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Vector Manufactured
Table 26.11 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Table 26.12 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Table 26.13 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Table 26.14 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Continents)
Table 26.15 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Countries)
Table 26.16 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Table 26.17 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facilities (Continents)
Table 26.18 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facilities (Countries)
Table 26.19 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Purpose of Production
Table 26.20 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Production
Table 26.21 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Table 26.22 Vector and Gene Therapy Manufacturers (Non-Industry Players): Cumulative Trend by Year of Establishment
Table 26.23 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Vector Manufacturing Facilities (Continents)
Table 26.24 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Vector Manufacturing Facilities (Countries)
Table 26.25 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Purpose of Production and Location of Vector Manufacturing Facilities
Table 26.26 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Scale of Production
Table 26.27 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Vector Manufactured
Table 26.28 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Scale of Production and Type of Vector Manufactured
Table 26.29 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Application Area
Table 26.30 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Technology
Table 26.31 Vector and Gene Therapy Manufacturing Technologies: Distribution by Purpose of Technology
Table 26.32 Vector and Gene Therapy Manufacturing Technologies: Distribution by Scale of Production
Table 26.33 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Vector Manufactured
Table 26.34 Vector and Gene Therapy Manufacturing Technologies: Distribution by Application Area
Table 26.35 Most Active Players: Distribution by Type of Technology
Table 26.36 Merck KGaA: Annual Revenues, 2014 - H1 2020 (EUR Billion)
Table 26.37 Merck KGaA: Annual Revenues by Business Sector, 2019 (EUR Billion)
Table 26.38 bluebird bio: Annual Revenues, 2014 - H1 2020 (USD Million)
Table 26.39 Emergent BioSolutions: Annual Revenues, 2016 - 9M 2020 (USD Million)
Table 26.40 FUJIFILM Holdings: Annual Revenues, 2013 - Q1 FY 2021 (JPY Billion)
Table 26.41 FUJIFILM Holdings: Revenues by Business Divisions, FY 2020 (JPY Billion)
Table 26.42 Spark Therapeutics: Annual Revenues, 2014 - 9M 2019 (USD Million)
Table 26.43 Lonza: Annual Revenues, 2014 - H1 2020 (CHF Billion)
Table 26.44 MolMed: Annual Revenues, 2013 - H1 2020 (EUR Million)
Table 26.45 Novasep: Annual Revenues, 2013 - 10M 2018 (EUR Million)
Table 26.46 Oxford BioMedica: Annual Revenues, 2014-H1 2020 (GBP Million)
Table 26.47 Sanofi: Annual Revenues, 2014 - H1 2020 (EUR Billion)
Table 26.48 uniQure: Annual Revenues, 2014 - H1 2020 (USD Million)
Table 26.49 Wuxi AppTec: Annual Revenues, 2017 - H1 2020 (RMB Million)
Table 26.50 Recent Partnerships: Cumulative Year-wise Trend, 2015 - 2020 (till September)
Table 26.51 Recent Partnerships: Distribution by Type of Partnership, 2015 - 2020 (till September)
Table 26.52 Recent Partnerships: Distribution by Type and Year of Partnership, 2015 - 2020 (till September)
Table 26.53 Recent Partnerships: Distribution by Scale of Operation
Table 26.54 Recent Partnerships: Distribution by Type of Vector
Table 26.55 Recent Partnerships: Distribution by Therapeutic Area
Table 26.56 Most Active Players: Distribution by Number of Partnerships
Table 26.57 Recent Partnerships: Geographical Analysis
Table 26.58 Recent Partnerships: Intercontinental and Intracontinental Agreements
Table 26.59 Recent Expansions: Cumulative Year-wise Trend, 2015 - 2020 (till September)
Table 26.60 Recent Expansions: Distribution by Type of Expansion, 2015 - 2020 (till September)
Table 26.61 Recent Expansions: Distribution by Type and Year of Expansion, 2015 - 2020 (till September)
Table 26.62 Recent Expansions: Distribution of Amount Invested by Key Players
Table 26.63 Recent Expansions: Distribution by Scale of Operation
Table 26.64 Recent Expansions: Distribution by Type of Vector
Table 26.65 Recent Expansions: Distribution by Application Area
Table 26.66 Most Active Players: Distribution by Number of Expansions
Table 26.67 Recent Expansions: Intercontinental and Intracontinental Expansions
Table 26.68 Recent Expansions: Distribution by Location of Expansion Project
Table 26.69 Viral Vector and Plasmid DNA Cost Price Analysis: Vector Production Process and Relative Costs Involved
Table 26.70 Global Installed Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Type of Vector Manufactured (in Liters)
Table 26.71 Global Installed Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (in Liters)
Table 26.72 Global Installed Viral Vector Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
Table 26.73 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
Table 26.74 Global Installed Viral Vector Manufacturing Capacity: Distribution by Company Size (in Liters)
Table 26.75 Global Installed Viral Vector Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Table 26.76 Global Installed Viral Vector Manufacturing Capacity: Distribution by Scale of Production (in Liters)
Table 26.77 Global Installed Viral Vector Manufacturing Capacity: Distribution by Geographical Location of Viral Vector Manufacturing Facilities (in Liters)
Table 26.78 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Company Size (in Liters)
Table 26.79 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Table 26.80 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Scale of Production (in Liters)
Table 26.81 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Location of Plasmid DNA Manufacturing Facilities (in Liters)
Table 26.82 Global Clinical Demand for Viral Vector and Plasmid DNA, 2021-2030 (Thousand Patients)
Table 26.83 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector Manufactured (Thousand Patients)
Table 26.84 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy (Thousand Patients)
Table 26.85 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Therapeutic Area (Thousand Patients)
Table 26.86 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location (Thousand Patients)
Table 26.87 Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients)
Table 26.88 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector (Thousand Patients)
Table 26.89 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy (Thousand Patients)
Table 26.90 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Therapeutic Area (Thousand Patients)
Table 26.91 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location (Thousand Patients)
Table 26.92 Global Viral Vector Manufacturing: Demand and Supply (Scenario 1), 2021-2030
Table 26.93 Global Viral Vector Manufacturing: Demand and Supply (Scenario 2), 2021-2030
Table 26.94 Global Viral Vector Manufacturing: Demand and Supply (Scenario 3), 2021-2030
Table 26.95 Viral Vector and Plasmid DNA Manufacturing Market, 2021-2030 (USD Million)
Table 26.96 Viral Vector and Plasmid DNA Manufacturing: Distribution by Type of Vector Manufactured, 2021-2030 (USD Million)
Table 26.97 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.98 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Therapeutic Area, 2021, 2025 and 2030 (USD Million)
Table 26.99 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Scale of Operation, 2021-2030 (USD Million)
Table 26.100 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Purpose of Production, 2021-2030 (USD Million)
Table 26.101 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.102 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.103 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Product: Distribution by Therapeutic Area, 2021, 2025 and 2030 (USD Million)
Table 26.104 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2021, 2025 and 2030 (USD Million)
Table 26.105 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Type of Vector Manufactured, 2021, 2025 and 2030 (USD Million)
Table 26.106 AAV Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.107 AAV Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 26.108 AAV Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.109 Adenoviral Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.110 Adenoviral Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 26.111 Adenoviral Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.112 Lentiviral Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.113 Lentiviral Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 26.114 Lentiviral Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.115 Retroviral Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.116 Retroviral Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 26.117 Retroviral Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.118 Plasmid DNA Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.119 Plasmid DNA Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 26.120 Plasmid DNA Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.121 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.122 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Phase of Development, 2021-2030 (USD Million)
Table 26.123 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2020, 2025 and 2030 (USD Million)
Table 26.124 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Type of Vector, 2021-2030 (USD Million)
Table 26.125 AAV Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.126 AAV Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2021-2030 (USD Million)
Table 26.127 AAV Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.128 Adenoviral Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.129 Adenoviral Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2021-2030 (USD Million)
Table 26.130 Adenoviral Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.131 Lentiviral Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.132 Lentiviral Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2021-2030 (USD Million)
Table 26.133 Lentiviral Vector Manufacturing Market for Clinical Candidate: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.134 Retroviral Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.135 Retroviral Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2021-2030 (USD Million)
Table 26.136 Retroviral Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.137 Plasmid DNA Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.138 Plasmid DNA Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2021-2030 (USD Million)
Table 26.139 Plasmid DNA Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.140 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.141 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Therapeutic Area, 2021, 2025 and 2030 (USD Million)
Table 26.142 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Animal Model Used, 2021-2030 (USD Million)
Table 26.143 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Geography, 2021, 2025 and 2030 (USD Million)
Table 26.144 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Type of Vector Manufactured, 2021-2030 (USD Million)
Table 26.145 AAV Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.146 AAV Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2021-2030 (USD Million)
Table 26.147 AAV Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.148 Adenoviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.149 Adenoviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2021-2030 (USD Million)
Table 26.150 Adenoviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.151 Lentiviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.152 Lentiviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2021-2030 (USD Million)
Table 26.153 Lentiviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.154 Retroviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.155 Retroviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2021-2030 (USD Million)
Table 26.156 Retroviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.157 Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.158 Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2021-2030 (USD Million)
Table 26.159 Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.160 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Type of Vector Manufactured, 2021-2030 (USD Million)
Table 26.161 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Scale of Operation, 2021-2030 (USD Million)
Table 20.162 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 26.163 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.164 Viral Vectors and Plasmid DNA Manufacturing Market, 2021-2030: COVID-19 Impact Informed Scenario (USD Billion)
Table 26.165 Survey Analysis: Distribution by Seniority Level of Respondents
Table 26.166 Survey Analysis: Distribution by Scale of Production
Table 26.167 Survey Analysis: Distribution by Type of Vector Manufactured
Table 26.168 Viral Vectors and Plasmid DNA Market: Distribution by Type of Vector Manufactured, 2021, 2025, 2030 (USD Million)

List of Companies

The following companies and organizations have been mentioned in the report.

  1. 4D Molecular Therapeutics
  2. Abbott
  3. AbbVie
  4. Abeona Therapeutics
  5. Abintus Bio
  6. Accinov(acquired by ABL Europe)
  7. Acucela
  8. Adaptimmune Therapeutics
  9. AdaptVac
  10. Addgene
  11. Aduro Biotech 
  12. Advanced BioScience Laboratories
  13. Advanced Biotherapeutics Consulting 
  14. Advantagene
  15. Advaxis
  16. Advent
  17. Adverum Biotechnologies
  18. Aevitas Therapeutics (a subsidiary of Fortress Biotech)
  19. AffyImmune Therapeutics
  20. AGC Biologics
  21. Agenzia Italiana del Farmaco
  22. Agilent Technologies
  23. Agilis Biotherapeutics (acquired by PTC Therapeutics)
  24. Applied Genetic Technologies (AGTC)
  25. Ajinomoto Althea
  26. Akdeniz University
  27. Akron Biotech
  28. Aldevron
  29. Allele Biotechnology
  30. Allergan
  31. Allife Medicine
  32. Allogene Therapeutics
  33. Alma Bio Therapeutics
  34. AlphaVax
  35. ALSTEM
  36. Althea Technologies 
  37. Altimmune
  38. Altor BioScience
  39. American Gene Technologies
  40. Amgen
  41. Amicus Therapeutics
  42. Ampersand Capital Partners
  43. AMSBIO
  44. Amsterdam BioTherapeutics Unit
  45. Amsterdam Molecular Therapeutics ( acquired by uniQure)
  46. Anaeropharma Science
  47. Anemocyte
  48. AnGes
  49. Angionetics
  50. Annapurna Therapeutics ( acquired by Avalanche Biotechnologies)
  51. apceth Biopharma
  52. ApollobBo
  53. Applied Biological Materials
  54. Applied Viromics
  55. Arcellx
  56. ARCO Design/Build 
  57. ArcticZymes Technologies
  58. Areta International
  59. Aruvant Sciences
  60. ASC Therapeutics
  61. Asklepios BioPharmaceutical
  62. Astellas Pharma
  63. AstraZeneca
  64. Atara Biotherapeutics
  65. Atlantic Bio
  66. Atsena Therapeutics
  67. ATVIO Biotech
  68. Audentes Therapeutics
  69. Aurora Biopharma
  70. Autolus Therapeutics
  71. Avecia Biologics 
  72. AveXis
  73. AVROBIO
  74. Axovant Gene Therapies
  75. Bamboo Therapeutics
  76. Batavia Biosciences
  77. Baylor College of Medicine
  78. BCM Families Foundation
  79. Beam Therapeutics
  80. Beckman Research Institute
  81. Beijing Biohealthcare Biotechnology
  82. Beijing Doing Biomedical
  83. Beijing HuiNengAn Biotech
  84. Beijing Immunochina Medical Science & Technology
  85. Beijing Mario Biotechnology
  86. Beijing Sanwater Biological Technology
  87. Bellicum Pharmaceuticals
  88. Benitec Biopharma
  89. BIA Separations
  90. Bioceltech Therapeutics
  91. BioCentriq
  92. Biogen
  93. Bio-Gene Technology
  94. BioInvent International
  95. BioMarin Pharmaceutical
  96. Biomay
  97. Biomiga
  98. Bionic Sight
  99. BioNTech Innovative Manufacturing Service
  100. Bio-Rad Laboratories
  101. BioReliance
  102. BioVec Pharma
  103. Bioverativ
  104. Biovian
  105. BioVision
  106. Blue Sky BioServices
  107. bluebird bio
  108. Boehringer Ingelheim BioXcellence
  109. BoYuan RunSheng Pharma
  110. Brain Neurotherapy Bio
  111. Brammer Bio
  112. LNBio
  113. Bristol Myers Squibb
  114. California Institute of Technology
  115. Cambridge Gene Therapy
  116. Cancer Research UK
  117. Candel Therapeutics
  118. Carina Biotech
  119. Carmine Therapeutics
  120. CARsgen Therapeutics
  121. Cartesian Therapeutics
  122. Casey Eye Institute
  123. Castle Creek Biosciences
  124. Catalent Biologics
  125. Celgene
  126. Cell and Gene Therapy Catapult
  127. Cell Biolabs
  128. Cellectis
  129. CellGenTech
  130. Cellular Biomedicine Group
  131. CellVec
  132. Celonic
  133. Celsion
  134. Celyad Oncology
  135. Center for Breakthrough Medicines
  136. Centre for Commercialization of Regenerative Medicine
  137. Centre for Process Innovation
  138. CEVEC Pharmaceuticals
  139. CG Oncology
  140. Children’s Medical Research Institute (CMRI)
  141. China Immunotech (Beijing) Biotechnology
  142. Chongqing Precision Biotech
  143. Choroideremia Research Foundation
  144. Cincinnati Children's Hospital Medical Center
  145. City of Hope
  146. Clean Cells
  147. Clino
  148. Cobra Biologics
  149. Cognate BioServices
  150. CombiGene
  151. Copernicus Therapeutics
  152. Cornell University
  153. Creative Biogene
  154. Creative Biolabs
  155. CSL Behring
  156. Cytiva
  157. CytoMed Therapeutics
  158. Daiichi Sankyo
  159. Delphi Genetics
  160. Denali Therapeutics
  161. DINAQOR
  162. DNAtrix
  163. Duke University
  164. Dyno Therapeutics
  165. Editas Medicine
  166. ElevateBio
  167. Elixirgen Scientific
  168. Emergent BioSolutions
  169. Emory University School of Medicine
  170. enGene
  171. Epeius Biotechnologies
  172. Errant Gene Therapeutics
  173. Esteve
  174. eTheRNA immunotherapies
  175. EUFETS
  176. Eureka Biotechnology
  177. Eurofins Genomics
  178. Eurofins Scientific
  179. ExcellGene
  180. Exothera
  181. Expression Therapeutics
  182. Eyevensys
  183. Fate Therapeutics
  184. FerGene
  185. FIMA
  186. FinVector
  187. Five Prime Therapeutics
  188. Flash Therapeutics
  189. Flexion Therapeutics
  190. Florida Biologix
  191. Formula Pharmaceuticals
  192. Fortress Biotech
  193. Fosun Pharma
  194. Foundation Fighting Blindness
  195. Fraunhofer Institute for Toxicology and Experimental Medicine
  196. Freeline Therapeutics
  197. FUJIFILM Diosynth Biotechnologies
  198. Fundamenta Therapeutics
  199. GE Healthcare Life Sciences
  200. GEG Tech
  201. Genable Technologies
  202. Gene Therapy Research Institution
  203. GeneCopoeia
  204. GeneCure Biotechnologies
  205. GeneDetect
  206. GeneImmune Biotechnology
  207. Genelux
  208. GeneMedicine
  209. GeneOne Life Science
  210. Genethon
  211. GENEWIZ
  212. Genexine
  213. Genezen Laboratories
  214. GenIbet Biopharmaceuticals
  215. Genprex
  216. GenScript
  217. GenSight Biologics
  218. GenVec
  219. Gen-X
  220. Genzyme
  221. GeoVax Labs
  222. GIGA
  223. GlaxoSmithKline
  224. Gracell Biotechnologies
  225. Gradalis
  226. Green Cross LabCell
  227. Grousbeck Gene Therapy Center
  228. Guangdong Xiangxue Precision Medical Technology
  229. Guangdong Zhaotai InVivo Biomedicine
  230. Guangzhou Anjie Biomedical Technology
  231. Guangzhou FineImmune Biotechnology
  232. Gyroscope Therapeutics
  233. Hadassah Medical Organization
  234. Handl Therapeutics
  235. Harvard Gene Therapy Initiative
  236. Hebei Senlang Biotechnology
  237. Heidelberg University Hospital
  238. Helixmith
  239. Hemera Biosciences
  240. Henan Hualong Biotechnology
  241. Herantis Pharma
  242. Hitachi Chemical Advanced Therapeutics Solutions
  243. Holostem Terapie Avanzate
  244. Homology Medicines
  245. Hookipa Biotech
  246. HORAMA
  247. Hrain Biotechnology
  248. Huadao biomedical
  249. Huapont Life Sciences
  250. Human Stem Cells Institute (HSCI)
  251. Hunan Zhaotai Yongren Medical Innovation
  252. International AIDS Vaccine Initiative (IAVI)
  253. Icahn School of Medicine at Mount Sinai
  254. iCAR Bio Therapeutics
  255. iCarTAB BioMed
  256. iCell Gene Therapeutics
  257. ID Pharma
  258. Ilya Pharma
  259. Immatics
  260. Immune Design
  261. Immune Technology
  262. Immunocore
  263. Immunomic Therapeutics
  264. Imperial Innovations
  265. Indiana University
  266. Innovative Cellular Therapeutics
  267. Inovio Pharmaceuticals
  268. InProTher
  269. Institute of Medical Science Research Hospital
  270. Institute of Translational Health Sciences
  271. Instituto de Tecnologia Química e Biológica (ITQB)
  272. InvivoGen
  273. IPPOX Foundation
  274. IVERIC bio
  275. Janssen Pharmaceuticals
  276. Juno Therapeutics
  277. Juventas Cell Therapy
  278. JW Therapeutics
  279. KAEDI
  280. Kaneka Eurogentec
  281. Karolinska Institutet
  282. Kecellitics Biotech
  283. King’s College London
  284. Kite Pharma
  285. Kobe Biomedical Innovation Cluster
  286. Kolon TissueGene
  287. Kriya Therapeutics
  288. Krystal Biotech
  289. Kuur Therapeutics
  290. Laboratory of Digital Sciences of Nantes
  291. LakePharma
  292. Legend Biotech
  293. Lentigen Technology
  294. Leucid Bio
  295. Leuven Viral Vector Core
  296. LEXEO Therapeutics
  297. Lion TCR
  298. Lipigon Pharmaceuticals
  299. LogicBio Therapeutics
  300. Lokon Pharma
  301. Lonza
  302. Louisiana State University School of Veterinary Medicine
  303. Luina Bio
  304. Luminous BioSciences
  305. Lund University
  306. Lysogene
  307. Magee-Womens Research Institute
  308. Maine Medical Center Research Institute (MMCRI)
  309. Marino Biotechnology
  310. Massachusetts Eye and Ear
  311. Massachusetts General Hospital
  312. MassBiologics
  313. MaxCyte
  314. Mayflower Bioscience
  315. Mayo Clinic Cancer Center
  316. MD Anderson Cancer Institute
  317. Medac
  318. Medigene
  319. MedImmune
  320. MeiraGTx
  321. Memorial Sloan Kettering Cancer Center
  322. Merck
  323. Microsoft
  324. Mila’s Miracle Foundation
  325. MilliporeSigma
  326. Milo Biotechnology
  327. Miltenyi Biotec
  328. Minerva Biotechnologies
  329. MingJu Therapeutics
  330. Mitsubishi Tanabe Pharma
  331. Molecular Diagnostic Services
  332. MolMed
  333. Momotaro-Gene
  334. MultiVir
  335. Mustang Bio
  336. Myeloma Crowd
  337. Nanjing Bioheng Biotech
  338. Nantes Gene Therapy Institute
  339. Naobios
  340. National Cancer Institute
  341. National Center for Advancing Translational Sciences
  342. National Eye Institute
  343. National Human Genome Research Institute
  344. National Institute of Allergy and Infectious Diseases
  345. National Institute of Environmental Health Sciences
  346. Nationwide Children's Hospital
  347. Nature Technology
  348. Naval Medical Research Center
  349. Neurimmune
  350. NeuroCure
  351. Neurophth Therapeutics
  352. Neuroscience Center Zurich
  353. New Jersey Innovation Institute (NJII)
  354. NewLink Genetics
  355. NHS Blood and Transplant
  356. Nikon CeLL innovation
  357. Noga Therapeutics
  358. Norgen Biotek
  359. Nouscom
  360. Novartis
  361. Novasep
  362. Odylia Therapeutics
  363. Okairos
  364. Omnia Biologics
  365. Oncolys BioPharma
  366. OncoSec
  367. OncoSenX
  368. ORCA Therapeutics
  369. Orchard Therapeutics
  370. Oregon Health & Science University
  371. OS Therapies (OST)
  372. Otonomy
  373. Oxford BioMedica
  374. Oxford Genetics
  375. OXGENE
  376. OZ Biosciences
  377. PACT Pharma
  378. Pall Biotech
  379. Paragon Bioservices
  380. PeriphaGen
  381. PersonGen BioTherapeutics
  382. Pfizer
  383. PharmaCell
  384. PhorMed
  385. Pinze Lifetechnology
  386. PlasmidFactory
  387. Poseida Therapeutics
  388. Precigen
  389. Precision BioSciences
  390. Prevail Therapeutics
  391. ProBioGen
  392. Progenics Pharmaceuticals
  393. ProMab Biotechnologies
  394. Protheragen
  395. Provecs Medical
  396. PsiOxus Therapeutics
  397. PTC Therapeutics
  398. Puresyn
  399. Quethera
  400. Regeneron Pharmaceuticals
  401. REGENXBIO
  402. ReiThera
  403. Renova Therapeutics
  404. Rentschler Biotechnologie
  405. Richter-Helm BioLogics
  406. Roche
  407. Rocket Pharmaceuticals
  408. Roswell Park Comprehensive Cancer Center
  409. Rubius Therapeutics
  410. SAB Technology
  411. SAFC
  412. Saiba
  413. Salk Institute for Biological Studies
  414. Sanford Burnham Prebys Medical Discovery Institute
  415. Sangamo Therapeutics
  416. Sanofi
  417. Santen Pharmaceutical
  418. Sarepta Therapeutics
  419. Sartorius Stedim Biotech
  420. Scancell
  421. Seattle Children's Research Institute
  422. Selecta Biosciences
  423. Servier
  424. Shanghai Biomed-union Biotechnology
  425. Shanghai Bioray Laboratory
  426. Shanghai Cell Therapy
  427. Shanghai GeneChem
  428. Shanghai Longyao Biotechnology
  429. Shanghai PerHum Therapeutics
  430. Shanghai Sunway Biotech
  431. Shanghai Unicar-Therapy Bio-medicine Technology
  432. Shenzhen Binde Biotechnology
  433. Shenzhen SiBiono GeneTech
  434. SignaGen Laboratories
  435. SillaJen
  436. Simcere Pharmaceutical
  437. Sinobioway Cell Therapy
  438. SIRION Biotech 
  439. Solid Biosciences
  440. Sorrento Therapeutics
  441. Spark Therapeutics
  442. SQZ Biotechnologies
  443. San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget)
  444. St. Jude Children's Research Hospital
  445. Stanford University
  446. Symbiosis Pharmaceutical Services
  447. Synpromics
  448. Synthace
  449. System Biosciences
  450. Takara Bio
  451. Takeda Pharmaceutical
  452. Targovax
  453. TCRCure Biopharma
  454. TCR2 Therapeutics
  455. tebu-bio
  456. Telethon Institute of Genetics and Medicine (TIGEM)
  457. Terry Fox Laboratory
  458. Tessa Therapeutics
  459. The Beijing Pregene Science and Technology
  460. Children's Hospital of Philadelphia
  461. Hong Kong Institute of Biotechnology
  462. The Jenner Institute
  463. The Michael J. Fox Foundation 
  464. The Native Antigen
  465. The Pregene (ShenZhen) Biotechnology
  466. The University of Tennessee Health Science Center
  467. TheraBiologics
  468. Theravectys
  469. Thermo Fisher Scientific
  470. Tianjin Mycure Medical Technology
  471. Timmune Biotech
  472. Tmunity Therapeutics
  473. Tolerion
  474. Touchlight Genetics
  475. Transgene
  476. Treeway
  477. Trizell
  478. Twist Bioscience
  479. TxCell
  480. UC Davis
  481. UK Cystic Fibrosis Gene Therapy Consortium
  482. Ultragenyx Pharmaceutical
  483. uniQure
  484. Universitat Autònoma de Barcelona-Vall d'Hebrón Institut de Recerca
  485. University College London
  486. University Medical Center Groningen
  487. University of Adelaide
  488. University of Eastern Finland
  489. University of Florida
  490. University of Iowa Carver College of Medicine
  491. University of Massachusetts Medical School
  492. University of Michigan Medical Center
  493. University of Minnesota
  494. University of North Carolina
  495. Clinical BioManufacturing Facility (University of Oxford)
  496. University of Pennsylvania
  497. University of Pittsburgh
  498. University of South Carolina School of Medicine
  499. University of Southampton
  500. University of Tokyo
  501. University of Virginia School of Medicine
  502. Unum Therapeutics (now Cogent Biosciences)
  503. Urovant Sciences
  504. UC San Diego School of Medicine
  505. USC School of Pharmacy
  506. UWELL Biopharma
  507. Vaccine Manufacturing and Innovation Centre (VMIC)
  508. Vaccitech
  509. VBL Therapeutic
  510. VCN Biosciences
  511. Vector Biolabs
  512. Vecura
  513. VGXI
  514. Vibalogics
  515. Vical
  516. Vigene Biosciences
  517. Vineti
  518. The Jackson Laboratory
  519. Viralgen
  520. Virapur
  521. ViraQuest
  522. ViroMed
  523. Virovek
  524. VirusTech
  525. VIVEbiotech
  526. Voyager Therapeutics
  527. Waisman Biomanufacturing
  528. Washington University School of Medicine
  529. Wellington Zhaotai Therapies
  530. Wuhan Bio-Raid Biotechnology
  531. Wuhan Sian Medical Technology
  532. WuXi AppTec
  533. Wyvern Pharmaceuticals
  534. Yufan Biotechnology
  535. Xiangxue Life Sciences
  536. Xpress Biologics
  537. XyloCor Therapeutics
  538. Xyphos Biosciences
  539. Yake Biotechnology
  540. Yposkesi
  541. Ziopharm Oncology

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com